Gallbladder and Pancreas

Ivonescimab Plus Gemcitabine–Cisplatin in Biliary Tract Cancer (BTC): Journal of Hepatology | July 2026

Introduction: Advanced biliary tract cancer (BTC) carries a poor prognosis, with limited improvements in survival despite the addition of immune checkpoint inhibitors to standard gemcitabine–cisplatin chemotherapy. This phase II trial evaluated ivonescimab, a novel PD-1/VEGF bispecific antibody, combined with chemotherapy as first-line treatment. Why was this study needed? Current first-line immunochemotherapy provides only modest survival benefit. Advanced BTC continues to have poor long-term outcomes. More effective first-line treatment strategies are urgently needed. Biomarkers predicting treatment response remain poorly defined. Novel immunotherapy combinations require prospective evaluation. Results: Ivonescimab plus gemcitabine–cisplatin demonstrated impressive antitumor activity, achieving a 66.7% objective response rate, 100% disease control rate, and a median overall survival of 16.8 months. The combination showed a manageable safety profile, with predominantly expected hematologic toxicities and no treatment-related deaths. MAP2K7 emerged as a potential biomarker of resistance, suggesting a future role in patient selection and development of combination therapies. Clinical Impact: This study suggests that ivonescimab-based immunochemotherapy may improve outcomes beyond current first-line standards for advanced biliary tract cancer. Although these encouraging findings require confirmation in randomized phase III trials, they highlight the promise of dual PD-1/VEGF blockade and biomarker-driven precision therapy. Bottom Line: Ivonescimab plus gemcitabine–cisplatin demonstrated encouraging efficacy and acceptable safety as first-line therapy for advanced biliary tract cancer. If confirmed in larger trials, it may become a new treatment option, with MAP2K7 serving as a potential biomarker to personalize therapy.

GLP-1 Receptor Agonists and Gallbladder Disease: UEG Journal | June 2026

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a cornerstone in the management of type 2 diabetes because of their excellent glycemic, cardiovascular, and weight-loss benefits. However, concerns remain regarding their potential association with gallbladder and biliary diseases. Why was this study needed? Previous studies suggested a possible increase in gallbladder complications with GLP-1 RAs, but long-term real-world data evaluating individual biliary outcomes and differences between specific GLP-1 agents have been limited. What did the study show? This large real-world cohort included over 156,000 patients with type 2 diabetes, with follow-up extending to three years. GLP-1 RA therapy was associated with higher risks of cholelithiasis, choledocholithiasis, cholecystitis, and subsequent cholecystectomy. No significant increase was observed in acute pancreatitis or the need for ERCP. The biliary risk varied among individual agents, with semaglutide and dulaglutide showing a higher risk of gallstones, whereas liraglutide and exenatide were not significantly associated with increased risk. Steatotic liver disease, obesity, and alcohol use independently increased the likelihood of gallbladder and biliary complications. Clinical Impact: The overall benefits of GLP-1 RAs continue to outweigh these modest biliary risks for most patients. Clinicians should remain vigilant in individuals with pre-existing gallstones, steatotic liver disease, obesity, or heavy alcohol use, and promptly evaluate new biliary symptoms during treatment. Take-Home Message: GLP-1 receptor agonists remain highly effective therapies for type 2 diabetes, but they are associated with a modest increase in gallbladder and biliary complications. Careful patient selection, counseling, and monitoring can help maximize benefits while minimizing biliary adverse events.

Remnant Duct Dilatation Rarely Signals IPMN Recurrence : Ann Surg | Jun 2026

Introduction: Patients undergoing pancreatoduodenectomy for non invasive intraductal papillary mucinous neoplasm (IPMN) require long-term surveillance because of the risk of disease recurrence in the pancreatic remnant. New pancreatic duct (PD) dilatation is commonly detected during follow-up imaging, but its clinical significance remains uncertain, often creating a dilemma regarding further investigation or completion pancreatectomy. Problem Statement: Although main pancreatic duct dilatation is a recognized radiological hallmark of IPMN, postoperative duct dilatation may also result from benign causes such as anastomotic changes, aging, pancreatitis, or physiological postoperative remodeling. Distinguishing benign ductal dilatation from true IPMN recurrence is essential to avoid unnecessary surgery while ensuring timely detection of invasive disease. Summary: This international multicenter study evaluated the natural history of remnant pancreatic duct dilatation following pancreatoduodenectomy for non invasive IPMN. During long-term surveillance, more than one-quarter of patients developed new pancreatic duct dilatation, making it a frequent postoperative finding. Older age and longer duration of follow-up were the only factors associated with duct enlargement, whereas the original IPMN subtype and preoperative duct diameter did not predict its development. Importantly, although duct dilatation frequently raised suspicion for recurrent IPMN, progression to invasive pancreatic cancer was exceptionally uncommon. Only a very small proportion of patients ultimately required completion pancreatectomy for invasive carcinoma, and most of these patients had high-grade dysplasia in the original surgical specimen, suggesting that initial pathological severity may be more informative than postoperative duct dilatation alone. The findings indicate that remnant pancreatic duct dilatation is often a physiological consequence of long-term postoperative changes rather than evidence of recurrent neoplasia. Clinically, these results support a cautious, surveillance-based approach rather than immediate surgical intervention when isolated duct dilatation is identified after pancreatoduodenectomy. Overall, the study provides reassuring evidence that new remnant duct dilatation is common but rarely represents clinically significant IPMN recurrence, helping refine postoperative surveillance strategies and reducing the risk of unnecessary completion pancreatectomy.

Post-Pancreatectomy Chyle Leak: Annals of Surgery | June 2026

This study evaluated 1,063 patients undergoing pancreatic surgery; 11% developed conventionally defined chyle leak. Most clinically relevant cases were grade B, while no grade C leaks were reported. A minimally invasive surgical approach was independently associated with a higher likelihood of chyle leak. Maximum daily drain output was also strongly associated with clinically relevant leakage. The key finding was that triglyceride-rich drainage was frequently not milky. More than one-third of patients had drain triglycerides ≥1.2 mmol/L despite the absence of classic milky-colored fluid. Patients with high-volume drainage ≥300 mL/day and elevated triglycerides had prolonged hospitalisation, even when the drainage appeared clear or non-milky. Their length of stay was comparable to that of patients with high-volume, triglyceride-rich, visibly milky drainage. In contrast, low-volume triglyceride-rich drainage had less clinical impact. These findings challenge reliance on drain appearance when diagnosing post-pancreatectomy chyle leak. Measuring both drain triglyceride concentration and daily output volume may identify clinically important lymphatic leakage more accurately. The current International Study Group for Pancreatic Surgery definition may therefore underestimate clinically relevant cases that lack a milky appearance. As this was an observational single-centre study, external validation is needed before formal diagnostic criteria are changed. Bottom line: After pancreatic surgery, high-volume triglyceride-rich drainage should be managed as a clinically relevant chyle leak even when it is not milky.

Immediate Necrosectomy Accelerates Recovery in Walled-Off Necrosis : Gastroenterology | Jul 2026

Introduction: Endoscopic ultrasound (EUS)-guided drainage has become the preferred minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves necrosectomy for patients who fail to improve after drainage alone, some experts advocate earlier intervention to accelerate resolution of infected or symptomatic necrosis. Problem Statement: Although the step-up strategy minimizes procedural interventions, delayed necrosectomy may prolong inflammation, hospital stay, and recovery. Whether immediate DEN following EUS-guided drainage improves clinical outcomes without increasing complications has not been established in prospective randomized trials. Summary: The WONDER-01 trial is the first randomized study to directly compare immediate DEN with a drainage-oriented step-up strategy in patients undergoing endoscopic treatment for symptomatic necrotizing pancreatitis. The study demonstrated that immediate necrosectomy significantly shortened the time to clinical success, resulting in faster reduction of necrotic collections and earlier resolution of systemic inflammation. Patients receiving immediate DEN achieved recovery approximately two weeks earlier than those managed with the conventional step-up approach. Importantly, this benefit was achieved without an increase in procedure-related adverse events, mortality, or technical failure. As expected, all patients in the immediate intervention arm underwent necrosectomy, whereas less than half of patients in the step-up group ultimately required the procedure, highlighting the trade-off between faster recovery and greater procedural utilization. The findings suggest that early removal of necrotic debris may accelerate disease resolution in appropriately selected patients while maintaining a favorable safety profile. However, because many patients managed with drainage alone avoided necrosectomy altogether, treatment decisions should remain individualized. Overall, this landmark trial provides evidence that immediate DEN after EUS-guided drainage can shorten recovery time without compromising safety. The results challenge the traditional step-up paradigm and support consideration of earlier necrosectomy in selected patients with symptomatic walled-off necrosis, while emphasizing the need to balance procedural burden against potential clinical benefit.

Fatty Pancreas: A Hidden Burden in T2DM : Diabetes Res Clin Pract | June 2026

Introduction: Fatty pancreas disease (FPD), also known as intrapancreatic fat deposition, has emerged as an important metabolic condition closely linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Although ectopic fat accumulation in the liver has been extensively studied, pancreatic steatosis has received comparatively less attention despite growing evidence suggesting a role in β-cell dysfunction and metabolic deterioration. Problem Statement: The true prevalence of fatty pancreas in patients with T2DM remains uncertain because individual studies have reported highly variable estimates, influenced by differences in population characteristics, imaging modalities, and diagnostic criteria. A comprehensive assessment is needed to clarify the burden of FPD in diabetes and its potential clinical implications. Summary: This meta-analysis evaluated the prevalence of fatty pancreas disease among individuals with T2DM by pooling data from observational studies across diverse populations. The analysis demonstrated that fatty pancreas is highly prevalent in patients with T2DM, affecting approximately one-half of individuals with the disease. This finding highlights pancreatic steatosis as a common but often underrecognized component of the diabetic phenotype. Subgroup analyses suggested variability in prevalence across geographic regions and study settings, although the overall burden remained consistently high. Importantly, the prevalence was not significantly influenced by differences in imaging techniques or study period, indicating that the association between T2DM and pancreatic fat accumulation is robust across methodologies. These results support the concept that ectopic pancreatic fat may represent an important metabolic abnormality accompanying diabetes, potentially contributing to insulin resistance, impaired insulin secretion, and disease progression. The findings also reinforce growing interest in the pancreas as a target organ in metabolic disease, analogous to the liver in metabolic dysfunction–associated steatotic liver disease. From a clinical perspective, the study underscores the need for greater awareness of fatty pancreas in patients with T2DM and highlights the importance of future research to determine its prognostic significance, role in diabetes progression, relationship with pancreatitis and pancreatic cancer, and potential responsiveness to lifestyle and pharmacological interventions.

Selective Use of Biliary Drainage Supported in pCCA : BJS | Jun 2026

Introduction: Preoperative biliary drainage (PBD) is frequently used in patients with perihilar cholangiocarcinoma (pCCA) to relieve biliary obstruction before surgery. The proposed benefits include improved liver function, reduced jaundice, and optimization of the future liver remnant before major hepatectomy. However, biliary drainage is also associated with procedure-related complications, infection, and potential delays to definitive surgery. As a result, its routine use remains controversial. Problem Statement: Current practice varies widely because there is no clear consensus regarding which patients with resectable pCCA truly benefit from preoperative biliary drainage. Determining whether drainage improves or worsens postoperative outcomes is critical for optimizing perioperative management and reducing surgical risk. Summary: This large international multicenter study evaluated the impact of preoperative biliary drainage on postoperative outcomes in patients undergoing resection for perihilar cholangiocarcinoma. After adjustment for important baseline differences, the investigators found that patients who underwent biliary drainage experienced higher rates of major postoperative complications and, most notably, a significantly increased risk of posthepatectomy liver failure. When additional multivariable analyses were performed, the association with posthepatectomy liver failure remained robust, suggesting that biliary drainage may contribute to adverse postoperative liver-related outcomes in selected patients. These findings challenge the traditional assumption that preoperative drainage is universally beneficial before major liver resection for pCCA. Importantly, the study does not imply that biliary drainage should be abandoned altogether. Rather, it highlights that a subset of patients with resectable disease may proceed safely to surgery without routine drainage. The results support a more individualized approach in which decisions are guided by factors such as bilirubin levels, cholangitis, anticipated future liver remnant volume, and planned extent of resection. Given the retrospective nature of the analysis, definitive conclusions regarding causality cannot be drawn. Nevertheless, this represents one of the largest studies addressing this question and provides important evidence that routine preoperative biliary drainage should be carefully reconsidered. Future prospective studies are needed to better define which patients derive genuine benefit from drainage before surgery for perihilar cholangiocarcinoma.

Pancreatic Plasticity in Development and Disease : Nat Rev Gastroenterol Hepatol | May 2026

Introduction The pancreas represents one of the most dynamic models of cellular plasticity in human biology, where developmental fate decisions, tissue maintenance and regenerative responses are orchestrated through tightly regulated transcriptional and microenvironmental interactions. Recent advances in single-cell sequencing, spatial transcriptomics and lineage-tracing technologies have transformed understanding of pancreatic ontogeny, uncovering previously unrecognized cellular heterogeneity and transient developmental states. Pancreatic Cancer and Diabetes have increasingly been linked to dysregulated cellular plasticity pathways that recapitulate embryonic developmental programs. Problem Statement Despite major progress in defining pancreatic cell lineages, the mechanisms governing lineage commitment, dedifferentiation and regeneration remain incompletely understood. The relationship between developmental plasticity and pathological reprogramming in adult pancreatic tissue is particularly important, as injury-induced or disease-associated plasticity may contribute both to tissue repair and malignant transformation. Understanding how pancreatic cell identity is established and destabilized is critical for advancing regenerative medicine, stem-cell–based therapies and novel therapeutic strategies for pancreatic diseases. Summary This review provides an integrated overview of pancreatic development and cellular plasticity across embryogenesis, tissue homeostasis and disease. Pancreatic organogenesis is presented as a highly coordinated process involving reciprocal signalling between pancreatic endoderm and surrounding mesenchymal, endothelial, neural and immune compartments. These interactions are integrated through complex gene regulatory networks governed by lineage-defining transcription factors that determine endocrine, acinar and ductal cell fates. Single-cell and spatial analyses have identified substantial cellular diversity within pancreatic tissue, including rare and transient intermediate states that appear critical for lineage specification and adaptive remodelling. The review highlights how developmental plasticity mechanisms persist into adulthood, where they may become reactivated during injury, inflammation and neoplastic transformation. In particular, adult pancreatic cells can undergo dedifferentiation and lineage conversion in response to stress, resembling embryonic transcriptional programs. Such plasticity may support tissue regeneration but can also facilitate tumorigenesis in pancreatic cancer. Importantly, insights derived from developmental biology have enabled the generation of pancreatic cell types from human pluripotent stem cells, advancing the field of regenerative therapeutics for diabetes and pancreatic disorders. Emerging in vitro systems that better reproduce pancreatic microenvironmental niches and multicellular interactions are now providing increasingly physiologic platforms for disease modelling and therapeutic development. Overall, the review positions cellular plasticity as a central biological principle linking pancreatic development, regeneration and disease pathogenesis, with major implications for future translational strategies.

Rethinking Antibiotic Strategy in Infected Necrotizing Pancreatitis | Journal of Antimicrobial Chemotherapy

Introduction Infected necrotizing pancreatitis remains one of the most severe complications of acute pancreatitis and is associated with substantial morbidity, organ failure and mortality. Management relies on timely antimicrobial therapy combined with delayed, minimally invasive source control strategies. However, optimal antibiotic selection remains controversial because treatment is frequently empirical and microbiological confirmation is often unavailable early in the disease course. Problem Statement Traditional management has favored carbapenems because of presumed superior pancreatic penetration, yet increasing antimicrobial resistance and prolonged antibiotic exposure are reshaping the microbiology of infected pancreatic necrosis. At the same time, uncertainty persists regarding the true role of anaerobes, enterococci and fungal pathogens, while inappropriate empirical therapy remains common and may contribute to worse outcomes and multidrug resistance. Summary This comprehensive review highlights the evolving microbiological and pharmacokinetic landscape of infected necrotizing pancreatitis and challenges several long-standing assumptions regarding antimicrobial therapy. The microbiology is predominantly enteric, with Gram-negative organisms such as Escherichia coli and Klebsiella species remaining the dominant pathogens, although prolonged hospitalization and cumulative antibiotic exposure increasingly select for multidrug-resistant organisms, enterococci and fungal infections. Importantly, the review emphasizes that prophylactic antibiotics do not prevent infected necrosis or improve mortality and therefore should not be routinely used. The authors also question the traditional preference for carbapenems, noting that pharmacokinetic studies demonstrate that piperacillin-tazobactam and advanced-generation cephalosporins can achieve adequate penetration into necrotic pancreatic tissue, particularly when administered using extended infusion strategies. Molecular diagnostic studies further suggest that anaerobic organisms are substantially underrecognized by conventional culture techniques, supporting the rationale for empirical anaerobic coverage despite low reported culture yields. The review advocates for more individualized antimicrobial selection based on local resistance patterns, previous antibiotic exposure and evolving disease phase, while reserving carbapenems for multidrug-resistant infections or clinical failure. Overall, this work supports a more stewardship-focused, pharmacokinetically informed approach to antimicrobial therapy in infected necrotizing pancreatitis.

GCAL Score Helps Triage EUS in Unexplained Bile Duct Dilatation | Indian Journal of Gastroenterology

Introduction Unexplained common bile duct (CBD) dilatation is a frequent and often challenging clinical finding in gastroenterology practice. Although cross-sectional imaging may fail to identify a cause, endoscopic ultrasound (EUS) can detect clinically significant biliary and periampullary pathology that may require intervention. The challenge lies in identifying which patients are most likely to benefit from EUS while avoiding unnecessary procedures in low-risk individuals. Problem Statement Not all patients with isolated CBD dilatation harbor clinically meaningful pathology, yet routine EUS for all such patients is resource-intensive and may not be justified. A practical and validated clinical tool is needed to identify patients with a high likelihood of actionable findings and better guide EUS utilization in this increasingly common diagnostic scenario. Summary This study presents the development and prospective validation of the GCAL score, a practical risk stratification tool designed to identify patients with unexplained CBD dilatation who are most likely to benefit from EUS. The score incorporates five readily available clinical variables—gallbladder status, CBD diameter, age and liver function abnormalities—to predict the likelihood of actionable findings requiring endoscopic or surgical intervention. In both derivation and validation cohorts, EUS identified actionable pathology in approximately half of patients, underscoring its diagnostic value in this setting. The GCAL score demonstrated strong predictive performance and reliably distinguished patients at higher risk of clinically significant findings from those less likely to benefit from further invasive evaluation. Importantly, the model performed particularly well in prospective validation, supporting its clinical applicability in routine practice. These findings provide a simple and clinically relevant framework for triaging EUS in patients with unexplained bile duct dilatation and may help optimize procedural selection, improve diagnostic efficiency and reduce unnecessary investigations.

SPINK1 p.Asn34Ser: Gastroenterology | May 2026

Introduction The SPINK1 gene encodes the pancreatic secretory trypsin inhibitor, a key protective molecule that prevents premature trypsin activation within the pancreas. Dysfunction of this pathway is central to the pathogenesis of chronic pancreatitis. Among genetic variants, the p.Asn34Ser mutation has long been recognized as a major risk factor, yet its exact mechanism has remained unclear despite decades of research. Problem Statement A major paradox has existed in the field: The p.Asn34Ser variant is strongly associated with chronic pancreatitis risk, yet no consistent defect at the protein level has been identified. This has raised a critical question—does the pathogenic effect lie not in protein function, but at the level of gene expression? Summary This study supports the concept that the p.Asn34Ser variant acts through reduced messenger RNA expression rather than altered protein function. The variant exists within a larger haplotype containing multiple linked regulatory changes, particularly in the 5′ region of the gene. Emerging evidence suggests that these linked variants may disrupt transcription factor binding sites, leading to decreased SPINK1 mRNA production. Reduced mRNA levels would ultimately lower effective trypsin inhibitor availability within pancreatic acinar cells, predisposing to uncontrolled trypsin activity and chronic inflammation. Importantly, prior studies showing near-normal or even elevated protein levels may reflect compensatory mechanisms or differences in systemic versus local pancreatic expression. Overall, this work shifts the understanding of SPINK1-associated pancreatitis from a structural protein defect to a regulatory gene expression disorder, offering new insights into disease mechanisms and potential therapeutic targets.

Rome V Gallbladder and Sphincter of Oddi Disorders: Gastroenterology | May 2026

The Rome V Gallbladder and Sphincter of Oddi Disorders chapter substantially modernizes this field by moving away from historically overused functional labels and procedure-driven diagnosis toward a more restrictive, symptom-based, harm-minimizing approach. The major theme throughout the chapter is clear: these disorders have been over diagnosed, invasive interventions have been overused, and Rome V now prioritizes careful phenotyping, exclusion of structural disease, objective evidence of obstruction, and conservative management before procedural therapy. 1. Rome V Reframes Gallbladder and Sphincter Disorders as Over diagnosed, High-Risk Syndromes One of the most important conceptual shifts in Rome V is the explicit acknowledgment that dysfunctional gallbladder disorder (DGBD) and sphincter of Oddi disorder (SOD) have historically been over diagnosed and overtreated. Rome V emphasizes that many patients previously labeled with gallbladder or sphincter dysfunction likely have a more typical disorder of gut–brain interaction (DGBI), not a primary pancreaticobiliary motor disorder. This is a major conceptual shift because it fundamentally changes the threshold for: diagnosing DGBD/SOD, recommending cholecystectomy, and performing ERCP. Rome V repeatedly emphasizes minimizing harm, given that both cholecystectomy and ERCP carry meaningful procedural risk. 2. “Typical Biliary Pain” Is Now the Central Diagnostic Gatekeeper Rome V makes typical biliary pain the cornerstone of diagnosis for both DGBD and biliary SOD. This is arguably the single most important practical update in the chapter because symptom quality now drives diagnostic confidence more strongly than legacy functional testing. Rome V Definition of Typical Biliary Pain Pain in the epigastrium and/or right upper quadrant with all of the following: acute onset, lasts ≥20 minutes to several hours, episodic (not daily continuous pain), severe enough to interrupt activities or prompt urgent evaluation, unrelated to bowel movements, not relieved by acid suppression or positional change. Supportive features: nausea/vomiting, radiation to back/right scapula, postprandial occurrence, nocturnal awakening. Rome V specifically clarifies that biliary pain is typically steady, not colicky, and is often epigastric rather than strictly RUQ, correcting two longstanding clinical misconceptions. The pain-pattern figure on page 2 (Figure 1) is especially useful because it contrasts the sustained pattern of biliary pain with renal colic and intestinal colic. 3. Gallbladder Ejection Fraction (GBEF) Is No Longer a Rome Diagnostic Criterion for DGBD This is one of the most practice-changing updates in the chapter. Rome V removes gallbladder ejection fraction (GBEF) from the supportive diagnostic criteria for dysfunctional gallbladder disorder (DGBD) because evidence that cholescintigraphy predicts response to cholecystectomy remains weak and inconsistent. The chapter is explicit that: typical biliary pain predicts response to surgery better than cholescintigraphy, and GBEF should no longer be treated as a primary diagnostic determinant. This is one of the most important Rome V departures from older surgical practice. 4. DGBD Now Requires Watchful Waiting Before Surgery A major Rome V change is the addition of a preoperative observation period for suspected DGBD. Rome V now recommends that symptoms should persist despite a trial of conservative/nonoperative management before cholecystectomy is considered. This is a major shift because it explicitly discourages reflex cholecystectomy. The rationale is highly practical: DGBD is benign, does not cause life-threatening complications, and symptoms may resolve spontaneously in up to 50% of patients. Rome V therefore recommends a 3–6 month period of watchful waiting in most patients to reduce unnecessary cholecystectomy. This is one of the most important harm-reduction changes in the chapter. 5. Cholecystectomy for DGBD Is Now Reserved for Strictly Selected Patients Rome V takes a much more restrictive approach to cholecystectomy in DGBD. Cholecystectomy is appropriate only when: the patient clearly meets criteria for typical biliary pain, structural disease is excluded, symptoms persist after observation, and symptom burden remains clinically meaningful. This is a substantial narrowing of operative candidacy. The evaluation algorithm on page 5 (Figure 3) is one of the most clinically useful additions because it formalizes: exclusion of alternate etiologies, nonoperative trial, reassessment at 3–6 months, and only then consideration of surgery. 6. Sphincter of Oddi Manometry Is No Longer Part of Rome Criteria One of the most important technical changes in Rome V is the removal of sphincter of Oddi manometry from diagnostic criteria. This is a major departure from historical practice. Rome V removes manometry because it is: poorly reproducible, insufficiently sensitive, not reliably predictive, and no longer clinically justifiable in routine practice. The chapter explicitly notes that sphincter manometry has now been largely abandoned in clinical practice. This is one of the most consequential procedural de-escalations in Rome V. 7. Biliary SOD Type III Has Effectively Been Eliminated Rome V effectively abandons Type III SOD. This is one of the most important and practice-changing updates in the chapter. Following the landmark EPISOD trial, patients with biliary-type pain but no objective evidence of biliary obstruction are no longer considered to have a primary sphincter disorder. Instead, these patients are now understood to most likely have another DGBI. This is a major conceptual correction and substantially reduces inappropriate ERCP. 8. Biliary SOD Now Requires Objective Evidence of Obstruction Rome V now applies the term biliary SOD only to patients with: typical biliary pain, elevated liver tests and/or biliary dilation, and no stones or structural obstruction. This is one of the most important diagnostic tightening measures in Rome V. The implication is simple and clinically important: No objective evidence of biliary obstruction = no biliary SOD diagnosis. 9. Supportive Tests for Biliary SOD Have Been Removed Rome V removes the historical supportive tests for biliary SOD: normal amylase/lipase, sphincter manometry, hepatobiliary scintigraphy. These were removed because they lack sufficient diagnostic reliability or predictive value. This reflects both evidence evolution and current real-world practice. 10. ERCP for Biliary SOD Is Now Far More Restrictive Rome V strongly narrows the role of ERCP in suspected biliary SOD. ERCP is now primarily reserved for: patients with convincing biliary obstruction, probable SO stenosis, or clinically meaningful objective evidence suggesting true obstructive physiology. The evaluation algorithm on page 8 (Figure 5) is especially important because it formalizes a graded approach: exclude alternatives, determine objective evidence burden, assess confounders (opioids, somatization, intermittent vs static abnormalities), and reserve ERCP for those with higher likelihood of benefit. This is one of the most important procedural gatekeeping changes in Rome V. 11. Chronic Opioid Use Is a Major Confounder in Suspected Biliary SOD Rome V explicitly highlights chronic opioid use as a major diagnostic confounder in biliary SOD. This is clinically important because opioids may cause: bile duct dilation, sphincter spasm, and biliary-type symptoms, without true primary sphincter disease. This is a highly relevant real-world caution and should directly influence ERCP decision-making. 12. Pancreatic SOD Is Now Restricted to Unexplained Recurrent Acute Pancreatitis (RAP) This is one of the most important Rome V changes. Rome V now restricts pancreatic SOD to patients with documented recurrent acute pancreatitis (RAP) after exclusion of other etiologies. This is a major narrowing of the diagnosis. Rome V explicitly states there is no evidence that pancreatic SOD causes isolated pancreatic pain in the absence of pancreatitis. This effectively eliminates “pancreatic SOD” as an explanation for unexplained pancreatic-type pain alone. 13. EUS Is Now the Preferred Test in Suspected Pancreatic SOD Rome V strongly prioritizes EUS in unexplained recurrent acute pancreatitis. This is one of the most important practical recommendations in the pancreatic SOD section. EUS is now the preferred modality to exclude: occult stones/sludge, ampullary lesions, pancreatic neoplasia, ductal abnormalities, and chronic pancreatitis. MRCP remains complementary (or an alternative where EUS is unavailable), but EUS is now the preferred first-line advanced test. 14. ERCP for Pancreatic SOD Remains Uncertain and Highly Selective Rome V remains cautious regarding ERCP in pancreatic SOD. Although observational studies suggest benefit in selected patients with recurrent pancreatitis, evidence remains inconsistent and high-quality randomized data remain insufficient. Accordingly, Rome V recommends: individualized decision-making, conservative management when feasible, and highly selective ERCP use given procedural risk. Clinical Bottom Line The Rome V Gallbladder and Sphincter of Oddi Disorders chapter is fundamentally a diagnostic de-escalation and procedural restraint document. Its major advances are: strict redefinition of typical biliary pain, removal of GBEF as a diagnostic criterion for DGBD, mandatory watchful waiting before cholecystectomy, removal of sphincter manometry, effective elimination of Type III SOD, requirement for objective biliary obstruction in biliary SOD, much stricter ERCP thresholds, recognition of opioids as a major confounder, and restriction of pancreatic SOD to unexplained recurrent acute pancreatitis. The single most important Rome V message is this: diagnosis now depends less on legacy functional testing and far more on strict symptom phenotyping, objective evidence, and procedural restraint.

Optimal Timing of Endoscopic Necrosectomy After Catheter Drainage: Gastroenterology/ May 2026

Introduction Management of necrotising pancreatitis has evolved toward a minimally invasive, step-up approach, where initial catheter drainage—either percutaneous or endoscopic—is followed by endoscopic necrosectomy only when required. A key unresolved clinical question is the optimal timing of necrosectomy after drainage, especially in patients who remain symptomatic. The goal is to balance two competing priorities: Avoid early aggressive intervention that may increase complications Prevent prolonged sepsis and clinical deterioration due to delayed source control Problem Statement Not all patients with necrotising pancreatitis improve after catheter drainage alone. A subset continues to have persistent sepsis, organ dysfunction, pain, or failure of clinical resolution, necessitating necrosectomy. The dilemma is: 👉 Should necrosectomy be performed early after drainage, or should it be delayed to allow better demarcation of necrosis? Current Understanding and Evidence-Based Approach 1. Step-Up Strategy Remains the Foundation All major data—including trials such as the PANTER trial and the TENSION trial—support a step-up approach: Start with drainage Escalate only if there is clinical non-response This principle is universally accepted. 2. Timing Is Not Fixed—It Is Clinical Condition–Driven There is no single “ideal time point” (e.g., day 7, day 14). Timing is dictated by: Persistence of sepsis or SIRS Ongoing organ failure Lack of clinical improvement after adequate drainage Imaging showing a significant solid necrotic burden 👉 Necrosectomy should be considered when drainage alone fails, rather than based on a predefined timeline. 3. Early Necrosectomy (<2 weeks) – Generally Avoided Early intervention is associated with: Poor demarcation of necrosis Increased bleeding risk Higher procedural complications Hence, necrosectomy is usually deferred until collections mature into walled-off necrosis (WON), typically around 3–4 weeks after onset. 4. Role of Catheter Drainage First Drainage achieves several key objectives: Reduces the infected fluid component Controls sepsis in a significant proportion (up to 30–50%) May avoid the need for necrosectomy altogether 👉 Patients who respond clinically should not undergo necrosectomy. 5. When to Proceed to Necrosectomy Endoscopic necrosectomy is indicated when there is: Persistent clinical sepsis despite adequate drainage Blocked or ineffective drainage due to solid debris Ongoing pain, gastric outlet obstruction, or biliary obstruction Imaging showing a large, solid necrotic burden not amenable to drainage alone 6. Optimal Practical Window In most real-world scenarios: Drainage is performed once collection is accessible (often ~3–4 weeks) Necrosectomy is performed 3–7 days after drainage if there is no improvement, or later, depending on the response 👉 The key is not too early, not unnecessarily delayed—but triggered by clinical need. 7. Endoscopic vs Surgical Timing Paradigm Compared to surgery, endoscopic necrosectomy allows: More gradual debridement Multiple staged sessions Lower physiological stress This enables a more flexible timing strategy, tailored to patient response. Practical Clinical Approach A reasonable algorithm: Diagnose infected or symptomatic necrotising pancreatitis Perform catheter drainage (endoscopic or percutaneous) Reassess clinically over 48–72 hours If improving → continue conservative management If not improving → evaluate: Drain position/function Solid necrosis burden Proceed to endoscopic necrosectomy when indicated Key Clinical Insight The concept of “optimal timing” is somewhat misleading. 👉 The real principle is: “Drain first, wait if possible, intervene when necessary.” Conclusion The timing of endoscopic necrosectomy after catheter drainage in necrotising pancreatitis is not protocol-driven but patient-driven. Early necrosectomy should be avoided unless clinically necessary, while delayed intervention should not compromise control of sepsis. The best outcomes are achieved by individualised decision-making, guided by clinical response, imaging findings, and adequacy of drainage rather than rigid timelines.

Chronic Pancreatitis- From Inflammation to Fibrosis: Gastroenterology | May 2026

Article Type: Review — Basic and Clinical Gastroenterology & Hepatology Introduction and Summary Chronic pancreatitis is a progressive fibro-inflammatory disease characterised by recurrent or persistent abdominal pain, exocrine insufficiency, and eventual endocrine failure. Traditionally viewed as a structural disease diagnosed by ductal changes or calcification, it is now increasingly understood as a dynamic biological process beginning with acinar cell injury and evolving through inflammation to irreversible fibrosis. This review highlights a critical gap in current practice: most patients are diagnosed at an advanced stage, when structural damage is already established, and therapeutic options are largely palliative. The authors emphasise the need to shift focus toward early disease mechanisms, particularly inflammation, and to develop therapies that can alter the natural course of the disease rather than simply manage its complications. Problem Statement The major challenge in chronic pancreatitis is not just treatment—it is late recognition and lack of disease-modifying therapy. Early-stage disease remains difficult to diagnose due to the absence of validated biomarkers and limited access to histopathology. As a result, intervention typically occurs when fibrosis, ductal distortion, and calcification are already established. Current treatment strategies—primarily endoscopic or surgical—focus on relieving ductal obstruction and managing pain. However, these approaches do not address the underlying inflammatory and fibrotic pathways driving disease progression. This has limited progress in developing therapies that can prevent progression, reduce fibrosis, or preserve pancreatic function. Key Concepts for Clinicians 1. Disease Begins with Acinar Cell Injury Chronic pancreatitis starts with repeated or sustained injury to acinar cells, triggered by factors such as alcohol, smoking, genetic predisposition, or metabolic stress. 2. Inflammation Is the Central Driver Following injury, a cascade of inflammatory responses is activated. Persistent inflammation leads to recruitment of immune cells and activation of pancreatic stellate cells. 3. Stellate Cells Drive Fibrosis Activated stellate cells are central to fibrosis. They produce extracellular matrix components, leading to progressive replacement of normal pancreatic tissue with fibrotic tissue. 4. Progression Is a Continuum The disease evolves from early inflammatory changes to late-stage fibrosis, ductal abnormalities, and calcification. Importantly, early stages may be reversible or modifiable, whereas late stages are largely irreversible. 5. Diagnosis Is Biased Toward Late Disease Most diagnoses rely on imaging features such as ductal dilatation and calcification, which represent advanced disease. Early chronic pancreatitis remains underdiagnosed. 6. Lack of Biomarkers Limits Early Detection There are no widely accepted biomarkers for early disease, making it difficult to identify patients at a stage where intervention could alter progression. 7. Current Therapies Are Mostly Symptomatic Endoscopic and surgical interventions focus on ductal decompression and pain relief. They do not target the underlying inflammatory or fibrotic processes. 8. Disease-Modifying Therapy Is the Unmet Need A major focus of research is identifying therapies that can interrupt inflammation, prevent stellate cell activation, and reduce fibrosis. 9. Emerging Therapies Target Pathophysiology New strategies are exploring anti-inflammatory, anti-fibrotic, and antioxidant pathways. These include repurposed drugs and novel agents aimed at altering disease biology rather than structure. 10. Personalized Approach Is the Future Given the heterogeneity of chronic pancreatitis, a patient-tailored strategy based on aetiology, stage, and dominant pathophysiological mechanism is essential. Clinical Relevance This review reinforces a paradigm shift: chronic pancreatitis should no longer be viewed purely as a structural disease requiring mechanical intervention, but as a biological disease driven by inflammation and fibrosis. For clinicians, this means greater emphasis on: Identifying patients at earlier stages Recognising ongoing inflammation even in the absence of overt structural changes Considering therapies that target disease mechanisms rather than only symptoms It also supports ongoing efforts toward drug repurposing and translational research, particularly in targeting inflammation and fibrosis pathways. Conclusion Chronic pancreatitis is a progressive disease driven by a sequence of acinar injury, inflammation, and fibrosis. Current management remains focused on late-stage complications due to challenges in early diagnosis and a lack of effective disease-modifying therapies. Future progress depends on improving early detection, understanding inflammatory pathways, and developing targeted treatments that can halt or reverse disease progression. A patient-tailored, mechanism-based approach represents the most promising direction for improving long-term outcomes.

SPINK1 p.Asn34Ser: Gastroenterology | May 2026

Introduction The SPINK1 gene encodes the pancreatic secretory trypsin inhibitor, a key protective molecule that prevents premature trypsin activation within the pancreas. Dysfunction of this pathway is central to the pathogenesis of chronic pancreatitis. Among genetic variants, the p.Asn34Ser mutation has long been recognised as a major risk factor, yet its exact mechanism has remained unclear despite decades of research. Problem Statement A major paradox has existed in the field: The p.Asn34Ser variant is strongly associated with chronic pancreatitis risk, yet no consistent defect at the protein level has been identified. This has raised a critical question—does the pathogenic effect lie not in protein function, but at the level of gene expression? Summary This study supports the concept that the p.Asn34Ser variant acts through reduced messenger RNA expression rather than altered protein function. The variant exists within a larger haplotype containing multiple linked regulatory changes, particularly in the 5′ region of the gene. Emerging evidence suggests that these linked variants may disrupt transcription factor binding sites, leading to decreased SPINK1 mRNA production. Reduced mRNA levels would ultimately lower effective trypsin inhibitor availability within pancreatic acinar cells, predisposing to uncontrolled trypsin activity and chronic inflammation. Importantly, prior studies showing near-normal or even elevated protein levels may reflect compensatory mechanisms or differences in systemic versus local pancreatic expression. Overall, this work shifts the understanding of SPINK1-associated pancreatitis from a structural protein defect to a regulatory gene expression disorder, offering new insights into disease mechanisms and potential therapeutic targets.

Gallbladder Polyps: Are We Still Over-Operating Despite New Guidelines? UEG Journal | July 2026

Introduction Gallbladder polyps are commonly detected incidentally, with a prevalence of up to 7% in adults. The vast majority are benign, while only a small fraction represent adenomas with malignant potential. Because imaging cannot reliably distinguish benign from premalignant lesions, clinical guidelines have traditionally recommended surveillance or cholecystectomy based on size and risk factors. Updated European guidelines in 2022 aimed to reduce unnecessary surgery, but their real-world impact remains uncertain. Problem Statement Revised guidelines for gallbladder polyps have not effectively reduced unnecessary cholecystectomies for benign lesions. Summary The POLYP study demonstrates that despite updated 2022 European guidelines, a significant proportion of patients continue to undergo unnecessary surgery and follow-up. Among patients undergoing cholecystectomy, only 9% had true adenomas, while nearly 70% had non-neoplastic polyps, and many had no significant pathology. Importantly, the revision of guidelines—mainly adjusting age criteria from 50 to 60 years—resulted in only a minimal reduction in surgeries. This suggests that current decision-making strategies remain insufficient to accurately identify patients who truly benefit from cholecystectomy. Clinically, this study highlights a persistent gap between guidelines and optimal care. It underscores the need for better risk stratification tools, potentially incorporating advanced imaging, biomarkers, or predictive models, to avoid overtreatment. The key takeaway is clear: most gallbladder polyps are benign, yet many patients still undergo unnecessary surgery—guidelines alone are not enough.

IPMN Surgery vs Surveillance: Annals of Surgical Oncology | April 2026

Introduction Intraductal papillary mucinous neoplasm presents a common yet challenging clinical dilemma—whether to operate or observe. The core issue is diagnostic uncertainty, as current imaging and clinical tools cannot reliably identify which lesions harbor high-grade dysplasia or invasive cancer. This creates a high-stakes decision environment where both overtreatment and undertreatment are real risks. Problem Statement There is significant uncertainty and variability in decision-making for IPMN due to inability to accurately predict malignancy risk, combined with differing patient and clinician perspectives. Summary This perspective strongly emphasizes that IPMN management is not purely a clinical algorithm but a preference-sensitive decision under uncertainty. Surgeons often differ in their thresholds for recommending surgery, while patients vary widely in their tolerance for cancer risk, fear of surgery, and willingness to undergo long-term surveillance. The article proposes shared decision-making (SDM) as the solution—integrating three essential components: individualized risk estimation, clear communication of trade-offs between surgery and surveillance, and elicitation of patient values. SDM helps align treatment decisions with what matters most to the patient rather than relying solely on physician-driven judgment. The key message is powerful and practical: 👉 In IPMN, the “right” decision is not universal—it depends on the patient. This framework promotes better risk communication, reduces unwarranted variation, and supports more patient-centered care while maintaining clinical expertise.

SMV Involvement in Pancreatic Cancer: Annals of Surgical Oncology | April 2026

Introduction Pancreatic ductal adenocarcinoma is a highly aggressive malignancy frequently involving adjacent vascular structures such as the superior mesenteric vein (SMV). Advances in surgical techniques now allow venous resection and reconstruction, expanding resectability in borderline cases. However, beyond the presence of vascular involvement, the anatomical location of SMV involvement may carry important implications for surgical complexity and oncological outcomes. Problem Statement The clinical impact of proximal versus distal SMV involvement in pancreatic cancer remains unclear, limiting precise surgical risk stratification and prognostication. Summary This study emphasizes that the location of SMV involvement is a critical determinant of outcomes in pancreatic cancer surgery. Proximal SMV involvement is associated with more aggressive disease behavior, greater technical difficulty during surgery, and potentially poorer survival outcomes compared to distal involvement. The findings suggest that current resectability assessments based solely on the presence of vascular involvement may be inadequate. Incorporating the pattern and location of venous involvement can refine patient selection, guide surgical planning, and improve perioperative decision-making. Clinically, this reinforces a key evolving concept: vascular involvement is not binary—its anatomical context matters. Integrating this into preoperative evaluation may lead to more personalized and outcome-driven management strategies in pancreatic cancer.

Fatty Pancreas in MASLD: JGH | March 2026

Introduction Metabolic dysfunction-associated steatotic liver disease is now recognized as a multisystem metabolic disorder affecting not only the liver but also cardiovascular, renal, and endocrine systems. Parallel to this, Fatty pancreas disease—defined by intrapancreatic fat deposition—is emerging as another manifestation of ectopic fat accumulation. Despite increasing recognition, the coexistence of FPD in MASLD and its clinical implications remain poorly defined, even though both conditions share common metabolic pathways such as obesity, insulin resistance, and systemic inflammation. Problem Statement The prevalence and clinical significance of fatty pancreas disease in MASLD patients are unclear, limiting its integration into routine metabolic risk assessment and management. Summary This systematic review and meta-analysis including over 21,000 patients demonstrates that fatty pancreas disease is highly prevalent in MASLD, affecting approximately 54% of patients. Interestingly, there is marked geographic variation, with lower prevalence in Asian populations compared to non-Asian cohorts. Clinically, MASLD patients with concomitant FPD exhibit a distinctly worse metabolic phenotype. They tend to be older, have higher BMI, and show significantly higher rates of diabetes, hypertension, and metabolic syndrome. This reinforces the concept that ectopic fat deposition is not organ-specific but represents a systemic metabolic burden. The study highlights an important shift in understanding—moving from a liver-centric view of MASLD to a “multi-organ fat disease” model involving liver, pancreas, and beyond. Although the prognostic implications are not fully established, the presence of FPD may identify a higher-risk metabolic subgroup. For clinicians, this suggests that pancreatic fat should not be ignored when incidentally detected on imaging. Future research is needed to determine whether FPD contributes to pancreatic dysfunction, pancreatitis, or cancer risk, and whether it should influence therapeutic strategies in MASLD.

Tirzepatide and Acute Pancreatitis: Pancreatology | March 2026

Introduction With the rapid rise of obesity and type 2 diabetes, incretin-based therapies such as Tirzepatide have transformed metabolic care. These agents offer substantial benefits in weight reduction and glycemic control, approaching outcomes seen with bariatric surgery. However, as their use expands globally, safety concerns—particularly the potential risk of acute pancreatitis—have come under increasing scrutiny. Given that pancreatitis has multifactorial causes, understanding whether tirzepatide independently contributes to this risk, and whether this risk is dose-dependent, is clinically important. Problem Statement There is uncertainty regarding whether tirzepatide increases the risk of acute pancreatitis and whether this risk varies across commonly used doses (5 mg, 10 mg, 15 mg). Summary This large meta-analysis of 19 randomized trials including over 15,000 patients provides reassuring evidence that acute pancreatitis with tirzepatide is extremely rare (≈0.22%) and shows no dose–response relationship across therapeutic doses. Comparative analyses between 5 mg, 10 mg, and 15 mg doses demonstrated no statistically significant differences in pancreatitis risk, and results remained consistent across multiple sensitivity and advanced statistical models. Importantly, patient-related factors such as age and sex did not significantly influence risk. However, limitations include short follow-up durations and industry-funded trials, highlighting the need for long-term real-world data. Clinically, tirzepatide appears safe from a pancreatitis standpoint, but vigilance remains essential—especially in patients with traditional risk factors such as gallstones, alcohol use, or hypertriglyceridemia.

Peripancreatic Vascular Involvement in AIP: CGH | March 2026

Introduction Autoimmune pancreatitis (AIP) is a unique IgG4-related inflammatory disease with generally favourable outcomes following glucocorticoid therapy. However, beyond pancreatic inflammation, extension into the peripancreatic vasculature can occur, leading to venous stenosis, collateral formation, and in severe cases, gastric varices. These vascular complications remain underrecognized and are not adequately addressed in existing diagnostic guidelines, despite their potential to cause life-threatening bleeding. Problem Statement There is limited large-scale evidence on the true prevalence, clinical significance, and treatment responsiveness of peripancreatic vascular involvement in AIP. Additionally, there is no clear strategy to identify patients at risk of gastric varices or variceal rupture, leading to potential missed opportunities for early intervention. Summary This multicenter Japanese study demonstrates that peripancreatic vascular involvement is common in AIP, occurring in over 50% of patients, most frequently affecting the splenic vein. Collateral formation was observed in 40%, and gastric varices were identified in approximately 11% of those undergoing endoscopy, with rare but serious cases of variceal rupture. Importantly, glucocorticoid therapy showed excellent efficacy, reversing venous stenosis in more than 90% of cases and improving collateral circulation in the majority. Severe splenic vein involvement emerged as a key predictor of gastric varices. These findings highlight the need for routine vascular assessment in AIP and selective endoscopic screening in high-risk patients to prevent fatal complications.

NAPAN Trial in Metastatic Pancreatic Cancer: EJC/ March 2026

Introduction: Metastatic pancreatic cancer continues to carry a dismal prognosis, with limited effective options after failure of first-line gemcitabine-based therapy. Liposomal irinotecan (nal-IRI) combined with 5-fluorouracil/leucovorin (5-FU/LV) is currently an established second-line standard. However, S-1, an oral fluoropyrimidine widely used in Asian populations, has shown promising efficacy and convenience, raising the possibility of an alternative combination strategy with nal-IRI. Problem Statement and Summary: The NAPAN trial was designed to evaluate whether nal-IRI plus S-1 could outperform the current standard nal-IRI plus 5-FU/LV in second-line treatment. However, the study failed to demonstrate superiority, with shorter progression-free survival and a trend toward inferior overall survival in the S-1 arm. While toxicity profiles were comparable, no clinical advantage was observed with S-1. These findings reinforce nal-IRI plus 5-FU/LV as the standard second-line regimen and highlight the ongoing challenge of improving outcomes in metastatic pancreatic cancer beyond current chemotherapy backbones.

GOLP in High-Risk Resectable Intrahepatic Cholangiocarcinoma NEJM, March 2026

Introduction Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer and carries a poor prognosis even after curative surgery. Recurrence rates exceed 50%, particularly in patients with high-risk features such as large tumours (>5 cm), vascular invasion, multifocal disease, lymph-node involvement, or elevated CA19-9. Until now, no neoadjuvant therapy has been established as standard treatment for resectable high-risk iCCA. The GOLP regimen—a combination of gemcitabine–oxaliplatin chemotherapy, lenvatinib (an anti-angiogenic agent), and the PD-1 inhibitor toripalimab—has shown encouraging activity in advanced biliary tract cancers. This phase 2–3 randomised trial evaluated whether neoadjuvant GOLP before surgery could improve outcomes in patients with resectable high-risk iCCA. Summary In this multicenter randomised trial, 178 patients with resectable high-risk intrahepatic cholangiocarcinoma were assigned to either: Neoadjuvant GOLP therapy followed by surgery and adjuvant capecitabine Upfront surgery followed by adjuvant capecitabine (control group) At a median follow-up of 16.9 months, the median event-free survival was significantly longer with neoadjuvant therapy (18.0 months) compared with the control group (8.7 months, P<0.001). Two-year overall survival was 79% in the neoadjuvant group versus 61% in the control group, suggesting a survival advantage, although the predefined statistical threshold was not met. The objective response rate to neoadjuvant therapy was approximately 55%, with major pathological response in 19% and pathological complete response in 5% of patients. Adverse events occurred in 97% of patients receiving GOLP, with grade ≥3 toxicity in 28%, mainly hematologic, but no treatment-related deaths were reported. Key Message Neoadjuvant GOLP therapy significantly improves event-free survival in patients with resectable high-risk intrahepatic cholangiocarcinoma, suggesting a promising strategy to reduce early recurrence and potentially improve long-term outcomes.

Glucose Addiction in Cholangiocarcinoma: Hepatoma Research, 2025

Introduction Cholangiocarcinoma (CCA) is the second most common primary liver cancer and is associated with poor prognosis due to late diagnosis and aggressive tumour biology. Increasing evidence links diabetes mellitus and chronic hyperglycemia with both the development and progression of CCA. Tumour cells demonstrate a strong dependence on glucose metabolism—a phenomenon termed “glucose addiction.” CCA cells frequently upregulate glucose transporters (GLUTs) and glycolytic enzymes, allowing them to utilise glucose for rapid energy generation through aerobic glycolysis (Warburg effect). Beyond energy production, glucose also fuels multiple biosynthetic and signalling pathways that support tumour proliferation, invasion, and resistance to therapy. Summary This review highlights how high glucose environments promote cholangiocarcinoma progression through metabolic and signalling mechanisms. Key mechanisms include: Enhanced glycolysis (Warburg effect): Upregulation of GLUT1, PKM2, HK2, PFK1, and LDHA increases glucose uptake and glycolytic flux, supporting rapid tumour growth. Activation of oncogenic pathways: Hyperglycemia stimulates signaling cascades such as PI3K–AKT–mTOR, HIF-1α, and MYC, which further drive tumor proliferation and metabolic reprogramming. Alternative glucose pathways: Glucose metabolites feed into the pentose phosphate pathway (PPP) and hexosamine biosynthetic pathway (HBP), generating nucleotides, lipids, and glycosylated proteins essential for cancer progression. Tumor microenvironment changes: Increased lactate production leads to acidic microenvironments, enhancing tumor invasion and immune evasion. Importantly, this metabolic dependency may represent an Achilles’ heel of CCA cells. Targeting glucose metabolism—through glycolytic inhibitors, GLUT blockade, or metabolic pathway inhibitors—offers promising therapeutic opportunities for future CCA treatment strategies.

Acute Pancreatitis to Pancreatic Damage and Diabetes: Gastroenterology | March 2026

Introduction Acute pancreatitis (AP) is often considered a self-limited illness once the acute episode resolves, with survival exceeding 95%. However, increasing evidence suggests that AP frequently initiates a cascade of long-term pancreatic complications, including recurrent acute pancreatitis (RAP), early chronic pancreatitis (ECP), chronic pancreatitis (CP), and progressive endocrine dysfunction such as prediabetes and diabetes mellitus. The Goulash-Plus study, a prospective multicenter cohort from the Hungarian Pancreatic Study Group, was designed to longitudinally track structural pancreatic changes and endocrine outcomes following AP, aiming to clarify when disease progression occurs and identify critical periods for monitoring. Summary In this ongoing prospective cohort study, 360 patients with AP were followed for four years. At baseline, most patients (74.7%) had a single AP episode without morphologic pancreatic changes. Over time, structural progression was substantial: the proportion of patients with RAP, ECP, or CP increased from 25.3% at baseline to 55.1% at 4 years. Among patients with a single AP episode initially, 35.1% developed morphologic progression. Endocrine dysfunction progressed even more dramatically. At baseline, 59% had normal glucose metabolism, but by four years, prediabetes or diabetes occurred in 76.4%, and diabetes alone increased from 13.6% to 39.2%. Notably, most progression—both structural and endocrine—occurred within the first two years after AP. These findings highlight AP as a major risk factor for chronic pancreatic disease and metabolic dysfunction, supporting structured follow-up with pancreatic imaging and glucose testing during the first two years after AP.

Metabolic Syndrome Increases Cholangiocarcinoma Risk- Hepatology Feb.26

This large population-based cohort study evaluated the relationship between metabolic syndrome (MetS) and the risk of cholangiocarcinoma (CCA), including both intrahepatic and extrahepatic subtypes. The study included nearly 4.9 million adults aged ≥40 years who underwent national health screening between 2012 and 2017, with follow-up through 2021. Over 35.9 million person-years, 6,117 cases of CCA were identified. Individuals with metabolic syndrome had a 20% higher risk of cholangiocarcinoma compared with those without MetS (adjusted HR 1.20). The increased risk was consistent across subgroups defined by age, sex, liver enzyme levels, and comorbidities. Importantly, the association applied to both intrahepatic and extrahepatic CCA. A clear dose–response relationship was observed: the more metabolic components present (central obesity, hypertension, hyperglycemia, dyslipidemia), the higher the CCA risk. Individuals with five metabolic components had a 67% increased risk compared with those without metabolic abnormalities. These findings remained robust after accounting for the competing risk of all-cause mortality. Clinical implication: Metabolic syndrome is not only a cardiovascular and hepatometabolic concern but also an independent risk factor for biliary tract malignancy. Aggressive management of metabolic risk factors may have potential implications for reducing cholangiocarcinoma incidence.

Blood-Based Early Detection for Pancreatic Cancer: Are We There Yet- Gastroenterology Feb.26

Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, largely because it is usually diagnosed late. Individuals with familial risk, pathogenic germline variants, or pancreatic cystic disease carry a substantially higher risk and are now included in surveillance programs. Observational data suggest that surveillance improves resectability and survival, even after accounting for lead-time bias. Current guideline-endorsed surveillance relies on endoscopic ultrasound (EUS) and MRI, performed every 6–12 months. While effective, these approaches are expensive, operator-dependent, invasive, and not universally accessible—fueling intense interest in blood-based molecular early detection tests. The promise: a validated serum biomarker panel The editorial discusses a phase 2 validation study of a commercial serum-based test (PancreaSure), which combines: multiple protein biomarkers, and CA 19-9, into a locked algorithm tested in blinded samples from early-stage PDAC cases and controls drawn largely from high-risk cohorts. The test outperformed CA 19-9 alone in detecting early-stage disease and showed similar performance for stage I and II cancers—an encouraging signal for early detection. The key concern: performance in the intended-use population Despite promising headline performance, the authors urge caution for several reasons: 1) Limited representation of truly high-risk individuals Only a minority of PDAC cases in the study had genetic or familial susceptibility—the very population for whom such a test would be clinically deployed. In this subgroup, the biomarker panel did not clearly outperform CA 19-9 alone. 2) Specificity drops outside hereditary-risk settings Test specificity declined notably in participants without genetic or familial risk—particularly those with abnormal imaging or symptoms but no cancer. This raises concern about false positives if the test is used beyond its narrow intended context. 3) Key real-world confounders were excluded Conditions such as chronic pancreatitis and biliary obstruction—common in high-risk populations and known to elevate biomarkers—were excluded from controls. This limits confidence in how the test would perform in routine surveillance clinics. 4) Not yet evaluated in pancreatic cyst surveillance Patients with pancreatic cysts and worrisome features—a major surveillance group—were not included, leaving a critical evidence gap. Bigger picture: feasibility and integration Even among high-risk individuals, pancreatic cancer remains rare, and uptake of germline testing is low. This makes prospective screening trials difficult and raises fundamental questions: 1. What level of sensitivity and specificity is good enough to justify use? 2. How should biomarker testing integrate with EUS/MRI—replace them, triage them, or simply add cost and complexity? 3. Will biomarker-based screening actually reduce pancreatic cancer–specific or overall mortality? Without answers to these questions, premature adoption risks overdiagnosis, anxiety, unnecessary procedures, and added societal cost. Bottom-line interpretation: Blood-based molecular tests for early pancreatic cancer detection are scientifically promising—but not yet ready to replace or meaningfully augment imaging-based surveillance. Robust prospective studies in clearly defined high-risk populations are still needed to determine: true clinical utility, impact on outcomes, and cost-effectiveness. One-line GastroAGI takeaway Encouraging biomarker data do not yet justify changing pancreatic cancer surveillance practice.

NLR and Acute Pancreaatitis - Front Med 2026

#### Overview The neutrophil-to-lymphocyte ratio (NLR) is a simple, cost-effective biomarker derived from routine blood tests. It measures the ratio of neutrophils (a type of white blood cell involved in inflammation) to lymphocytes (white blood cells associated with immune regulation). NLR has gained attention as a potential early predictor of severity, complications, and mortality in acute pancreatitis (AP). #### Clinical Utility in Acute Pancreatitis NLR has been systematically reviewed and analysed for its role in predicting outcomes in acute pancreatitis. It is particularly useful during the first 24–48 hours after hospital admission, a critical window for risk stratification. Key findings from the systematic review include: 1. **Prediction of Severe Disease**: - Elevated NLR at admission is consistently associated with a higher likelihood of severe acute pancreatitis (SAP), which often requires intensive care. - NLR dynamics (changes over time) during day 1 and day 2 improve the ability to identify patients at risk of persistent organ failure (POF). 2. **Identification of Infectious Complications**: - NLR has shown utility in predicting infection-related complications, such as infected pancreatic necrosis (IPN), which is a serious condition requiring timely intervention. 3. **Mortality Risk**: - An admission NLR greater than 12 has been associated with in-hospital mortality, making it a valuable tool for identifying patients with a poor prognosis. 4. **Discriminative Performance**: - NLR demonstrates acceptable sensitivity and specificity for early triage decisions, making it a practical option for emergency departments. - It remains clinically useful when combined with other scoring systems (e.g., APACHE II, BISAP) or laboratory markers (e.g., procalcitonin, CRP). #### Advantages of NLR - **Accessibility**: NLR can be calculated from routine blood tests, making it readily available without additional costs or delays. - **Reproducibility**: It is a simple and reliable measurement. - **Dynamic Monitoring**: NLR can be tracked over time to assess changes in inflammatory status, which is crucial for managing acute pancreatitis. #### Limitations and Considerations - **Time-Specific Thresholds**: The predictive accuracy of NLR depends on the timing of measurement (e.g., admission, 24 hours, 48 hours). Fixed thresholds may not account for dynamic changes. - **Etiological Factors**: The performance of NLR may vary based on the underlying cause of pancreatitis (e.g., biliary pancreatitis vs. hypertriglyceridemia). - **Integration with Other Tools**: While NLR is valuable, it is most effective when used alongside validated clinical scores and other biomarkers. #### Recommendations - The use of NLR for early triage in acute pancreatitis is recommended, particularly in the first 48 hours. - Time-specific thresholds should be locally calibrated to optimize sensitivity and specificity. - Combining NLR with clinical scores and other laboratory markers (e.g., CRP, procalcitonin) can enhance decision-making accuracy. #### Systematic Review Registration The systematic review evaluating NLR in acute pancreatitis is registered with PROSPERO (CRD420251169592), ensuring transparency and methodological rigour. ### Conclusion The neutrophil-to-lymphocyte ratio (NLR) is a promising biomarker for early risk stratification in acute pancreatitis. Its ability to predict severe disease, persistent organ failure, infectious complications, and mortality makes it a valuable tool for guiding clinical decisions during the critical early phase of hospitalisation. Future studies should focus on refining thresholds, validating findings across different populations, and integrating NLR into composite predictive models.

HTG-Induced Pancreatitis

### HTG-Induced Pancreatitis: Overview and Latest Treatments **What is HTG-Induced Pancreatitis?** HTG-induced pancreatitis refers to acute pancreatitis caused by severe hypertriglyceridemia (HTG), which is an abnormally high level of triglycerides in the blood. Triglycerides are a type of fat (lipid) found in the bloodstream, and their elevation can lead to inflammation of the pancreas. Acute pancreatitis is a potentially life-threatening condition characterized by inflammation of the pancreas, causing abdominal pain, nausea, vomiting, and systemic complications. When triglyceride levels exceed 1,000 mg/dL (11.3 mmol/L) — and particularly when they surpass 2,000 mg/dL (22.6 mmol/L) — the risk of developing pancreatitis increases significantly. HTG is the third most common cause of acute pancreatitis after gallstones and alcohol. **Pathophysiology:** - In severe HTG, triglycerides in the blood are hydrolyzed by pancreatic lipase into free fatty acids (FFAs). - Excess FFAs overwhelm the pancreas's buffering capacity, leading to toxic effects on pancreatic cells, local ischemia, and inflammation. - This cascade of events results in acute pancreatitis. --- ### Risk Factors for HTG-Induced Pancreatitis: 1. **Genetic predisposition**: Familial hyperlipoproteinemia or mutations in genes like LPL, APOC2, APOA5, and GPIHBP1. 2. **Secondary causes**: Uncontrolled diabetes mellitus, obesity, metabolic syndrome, hypothyroidism, pregnancy, alcohol abuse, and certain medications (e.g., estrogens, isotretinoin, beta-blockers, or antiretrovirals). 3. **Diet**: High-fat diets can exacerbate the condition in susceptible individuals. 4. **Other factors**: Poorly controlled lipid-lowering therapy or nonadherence to treatment. --- ### Clinical Presentation: - **Symptoms**: Severe epigastric pain radiating to the back, nausea, vomiting, and abdominal tenderness. - **Lab findings**: Elevated serum triglycerides (often >1,000 mg/dL), elevated pancreatic enzymes (amylase and lipase), and evidence of systemic inflammation. - **Imaging**: Abdominal CT or MRI may reveal pancreatic inflammation, necrosis, or fluid collections. --- ### Latest Treatment Strategies for HTG-Induced Pancreatitis: - **Supportive Care**: - **Fluid resuscitation**: Aggressive intravenous (IV) fluids (e.g., lactated Ringer's solution) to maintain hemodynamic stability and prevent complications. - **Pain management**: Use of opioid analgesics (e.g., morphine or fentanyl) for severe abdominal pain. - **Nutritional support**: Early enteral feeding (via nasogastric or nasojejunal tube) is preferred over parenteral nutrition to reduce the risk of infections and improve outcomes. - **Monitoring and management of complications**: - Monitor for systemic inflammatory response syndrome (SIRS), organ failure, and local complications (e.g., necrosis, abscess, or pseudocyst). - Treat complications such as infected pancreatic necrosis with antibiotics or surgical intervention if needed. --- #### 2. **Rapid Reduction of Triglycerides:** The goal is to reduce triglyceride levels rapidly, ideally below 500 mg/dL, to mitigate ongoing pancreatic damage. - **Insulin Infusion**: - Insulin lowers triglycerides by activating lipoprotein lipase (LPL), which breaks down circulating triglycerides. - Indicated in patients with concurrent diabetes, metabolic syndrome, or hyperglycemia. - Dose: Continuous IV insulin infusion with glucose monitoring to prevent hypoglycemia. - **Plasmapheresis (Therapeutic Plasma Exchange)**: - Plasmapheresis is a procedure that removes triglyceride-rich plasma and replaces it with fresh plasma or albumin. - It is considered in severe cases with extremely high triglycerides (>2,000 mg/dL) or when there is a poor response to medical therapy. - Plasmapheresis can rapidly lower triglycerides and improve symptoms, but access to this therapy may be limited. - **Heparin**: - Low-dose unfractionated heparin can stimulate lipoprotein lipase activity and reduce triglycerides. However, its use is controversial due to the risk of bleeding and limited evidence supporting its efficacy. --- #### 3. **Lipid-Lowering Medications:** Once the acute phase is stabilized, long-term lipid-lowering therapy is initiated to prevent recurrence. - **Fibrates** (e.g., fenofibrate, gemfibrozil): - First-line agents for lowering triglycerides in patients with hypertriglyceridemia. - They reduce hepatic production of triglycerides and increase triglyceride clearance. - **Omega-3 Fatty Acids**: - High-dose omega-3 fatty acids (e.g., 2-4 g/day of EPA/DHA) can effectively lower triglycerides. - They are often used as an adjunct to fibrates or statins. - **Statins**: - While primarily used for cholesterol reduction, statins can modestly lower triglycerides and reduce cardiovascular risk. - **Niacin**: - Niacin (vitamin B3) reduces triglycerides by inhibiting hepatic triglyceride synthesis. However, its use is limited by side effects like flushing and hepatotoxicity. --- #### 4. **Management of Underlying Conditions:** - **Diabetes management**: Tight glycemic control with insulin or oral hypoglycemic agents. - **Weight loss**: Lifestyle modifications, including weight loss and exercise, can reduce triglyceride levels. - **Dietary changes**: - Low-fat diet (<15% of total calories from fat). - Avoid simple sugars, alcohol, and refined carbohydrates. - **Alcohol cessation**: Essential for patients with alcohol-related HTG. --- #### 5. **Experimental and Emerging Therapies:** - **Gene Therapy**: - Research is ongoing into gene therapies targeting mutations in genes like LPL and APOC3 to treat familial hypertriglyceridemia. - **Apolipoprotein C-III (APOC3) Inhibitors**: - Drugs like volanesorsen (an antisense oligonucleotide targeting APOC3) have shown promise in reducing triglycerides in patients with familial chylomicronemia syndrome (FCS). - **ANGPTL3 Inhibitors**: - Angiopoietin-like protein 3 (ANGPTL3) inhibitors (e.g., evinacumab) are being studied for their ability to lower triglycerides by enhancing lipoprotein lipase activity. --- ### Prognosis and Prevention: - With prompt and appropriate management, most patients recover from HTG-induced pancreatitis without long-term complications. - Preventive strategies include strict lipid control, lifestyle modifications, and adherence to medical therapy to prevent recurrence. --- ### Key Takeaways: - HTG-induced pancreatitis is a serious condition requiring rapid diagnosis and treatment. - Acute management focuses on supportive care and rapid triglyceride reduction using insulin infusions or plasmapheresis. - Long-term management involves lipid-lowering therapies, lifestyle changes, and addressing underlying causes. - Emerging therapies such as APOC3 and ANGPTL3 inhibitors hold promise for patients with severe or refractory hypertriglyceridemia.

EUS -guided Biliary Drainage in acute cholecystitis(GIE, Jan-2026)

The article discusses the efficacy and clinical durability of EUS-guided gallbladder drainage (EUS-GBD) as a treatment for acute cholecystitis in high-risk surgical patients. Acute cholecystitis, which is an inflammation of the gallbladder, is traditionally treated with surgical intervention. However, in patients who are not candidates for surgery due to high risk, EUS-GBD has emerged as a reliable alternative. This minimally invasive procedure has been supported by recent guidelines over percutaneous transhepatic gallbladder drainage (PTGBD) in such cases. The study systematically analyzed data from 18 studies, including 701 patients, with follow-up periods exceeding 1 year. The technical success rate of EUS-GBD was 95.8%, and the clinical success rate was 94.3%. Recurrence of cholecystitis was low (4.2%), while readmission rates were 19% and reintervention rates were 6%. Stent patency was observed for an average of 418.8 days, and the need for repeat endoscopy due to stent obstruction or occlusion was minimal (2.9%). Overall, the procedure showed a low rate of adverse events. In conclusion, EUS-GBD is a technically effective, clinically durable, and safe treatment for acute cholecystitis in high-risk patients, offering a viable alternative to traditional surgical approaches with sustained long-term outcomes.

SIMBA Trial - GUT Jan 2026

The SIMBA Trial, as described in the provided context, was a triple-blind, randomised, controlled, superiority trial aimed at evaluating whether simvastatin could reduce the recurrence of pancreatitis in patients with recurrent acute pancreatitis (RAP) or acute-on-chronic flares in chronic pancreatitis (CP). The trial was conducted across 23 centres and included patients who had experienced at least two episodes of RAP or CP flares in the previous 12 months. ### Key Details and Findings from the SIMBA Trial: 1. **Objective**: The primary goal was to test the efficacy of simvastatin, a statin with anti-inflammatory properties, as a prophylactic treatment to prevent the recurrence of pancreatitis. 2. **Design**: - **Randomisation**: Patients were randomly assigned to receive either simvastatin or a placebo for 1 year. - **Blinding**: The trial was triple-blind, ensuring that patients, investigators, and statisticians were unaware of the treatment allocation. - **Primary Endpoint**: The recurrence of pancreatitis was the primary measure of the trial's success. 3. **Participants**: The target sample size was 144 patients, but due to slow recruitment, an interim analysis was conducted with 85 patients (42.1% women). 4. **Results**: - **Recurrence Rate**: - In the intention-to-treat analysis, no statistically significant difference was observed between the simvastatin group (46.2% recurrence) and the placebo group (44.4% recurrence). The odds ratio (OR) was 1.07 (95% CI 0.43 to 2.66; p=0.88). - In the per-protocol analysis, recurrence rates were 35.5% for simvastatin and 41.9% for placebo (OR 0.76, 95% CI 0.27 to 2.12; p=0.60). - **Time to Recurrence**: No significant differences were observed between the groups. - **Adverse Events**: Development of diabetes mellitus was more frequent in the simvastatin group (4 patients vs 0 patients in the placebo group; p=0.04). 5. **Conclusion**: - The trial did not demonstrate that simvastatin reduces the recurrence rate of pancreatitis. - The results may be underpowered due to the early termination of the study. - The observed association between statins (simvastatin) and new-onset diabetes mellitus warrants further investigation. 6. **Implications**: - While statins have anti-inflammatory properties, their role in preventing pancreatitis recurrence remains uncertain based on this trial. - The potential risk of new-onset diabetes mellitus in patients taking statins, particularly simvastatin, should be explored further in future studies. ### Note: The trial's results highlight the importance of adequately powered studies to draw definitive conclusions. Any further references to the SIMBA trial in publications, such as GUT in January 2026, may include additional analyses, follow-up studies, or insights based on the trial's findings.

Acute pancreatitis, DM and Gut Microbiota

Acute pancreatitis (AP) is a common inflammatory condition of the pancreas that often requires hospitalization. While the in-hospital mortality rate for AP has decreased significantly due to advancements in clinical management, postdischarge morbidity and mortality remain high. One of the significant postdischarge complications associated with AP is the development of diabetes mellitus (DM). Emerging evidence suggests that the gut microbiota plays a critical role in influencing both the severity of AP and the risk of developing DM after discharge. ### **Key Findings on Acute Pancreatitis, DM, and Gut Microbiota** #### **1. Gut Microbiota and Acute Pancreatitis** - The gut microbiota is the community of microorganisms residing in the gastrointestinal tract, which plays a crucial role in health and disease. - During an episode of AP, significant alterations in the gut microbiota (dysbiosis) are observed. These changes are associated with the severity of AP and clinical outcomes such as length of hospital stay and in-hospital mortality. - In severe AP, specific microbial species, such as short-chain fatty acid (SCFA) producers (e.g., *Parabacteroides distasonis*, *Enterocloster bolteae*, and *Lachnospiraceae* species), are over-represented, which may influence inflammation and recovery. #### **2. Postdischarge Complications of AP** - Patients recovering from AP are at risk for several long-term complications, including: - Recurrent acute pancreatitis (RAP) - Progression to chronic pancreatitis (CP) - Pancreatic exocrine insufficiency (PEI) - Development of diabetes mellitus (DM) - Pancreatic ductal adenocarcinoma (PDAC) - Postdischarge mortality rates in AP patients are significantly higher compared to the general population, particularly within the first 2 years after discharge. Cardiovascular events, sepsis, gastrointestinal malignancies, and cancer-related cachexia are common causes of death. #### **3. Diabetes Mellitus After Acute Pancreatitis** - DM is a frequent complication following AP, referred to as post-pancreatitis diabetes mellitus (PPDM). It is distinct from type 1 and type 2 diabetes and is associated with higher mortality and hospital readmission rates. - The development of DM post-AP is hypothesized to result from pancreatic damage, inflammation, and endocrine dysfunction caused by the initial episode of AP. #### **4. Role of Gut Microbiota in Predicting DM** - A recent study has shown that the composition of the gut microbiota at the time of hospital admission for AP is strongly associated with the risk of developing DM after discharge. - Using advanced genomic sequencing techniques (16S rRNA and metagenomics), researchers identified 11 differentially abundant microbial species in rectal swabs that were predictive of postdischarge DM. - Key findings include: - The gut microbiota at admission significantly differs between patients who later develop DM and those who do not. - A ridge regression model using these 11 microbial species achieved high predictive accuracy for postdischarge DM: - Area under the receiver operating characteristic curve (AUC): 94.8% in a matched cohort and 86.2% in the entire cohort. - Positive predictive value: 66.6% - Negative predictive value: 96% - Overall accuracy: 95% - This suggests that the gut microbiota could serve as a biomarker for identifying patients at high risk for developing DM after AP. #### **5. Clinical Implications** - The ability to predict postdischarge DM based on gut microbiota could transform the management of AP by enabling tailored surveillance and early interventions for high-risk patients. - Stratification of follow-up care based on microbial patterns may improve patient outcomes and reduce healthcare costs. - Understanding the role of specific gut bacteria and their metabolites in the pathogenesis of DM after AP could lead to the development of preventive strategies, such as: - Probiotics or prebiotics to restore healthy gut microbiota. - Dietary interventions to modulate microbial composition. - Targeted therapies to mitigate inflammation and pancreatic damage. ### **Conclusion** The connection between acute pancreatitis, diabetes mellitus, and gut microbiota represents a promising area of research with significant clinical implications. The gut microbiota at the time of AP admission not only correlates with disease severity but also serves as a powerful predictor of postdischarge complications, particularly DM. These findings pave the way for microbiota-based diagnostic tools and therapeutic strategies to improve the long-term outcomes of patients recovering from AP.

New-Onset Diabetes and Pancreatic Cancer

New-Onset Diabetes (NOD) and its link to Pancreatic Cancer, specifically Pancreatic Ductal Adenocarcinoma (PDAC), is an emerging area of medical research. Glycemically defined new-onset diabetes (GNOD) has been identified as a high-risk clinical state for PDAC. Below is a detailed explanation of the relationship between NOD and pancreatic cancer, based on the provided context: ### Key Findings and Insights: 1. **Increased Risk of PDAC After GNOD**: - GNOD is strongly associated with an increased short-term risk of developing PDAC. Prospective validation studies have confirmed that individuals with GNOD are at a significantly higher risk of PDAC compared to the general population. - Among 18,838 adults aged 50 years or older with GNOD, 82 cases of PDAC were diagnosed during follow-up. 2. **Incidence and Risk**: - The race-adjusted 3-year incidence of PDAC after GNOD was found to be 0.62%, which is substantially higher than the background population rates. - Different racial and ethnic groups exhibit varying levels of PDAC risk: - **Non-Hispanic White patients**: Highest 3-year PDAC incidence (0.84%) and standardized incidence ratio (SIR) of 6.4. - **Hispanic patients**: 3-year incidence of 0.40% and SIR of 4.2. - **African American patients**: 3-year incidence of 0.37% and SIR of 2.4. - **Asian/Pacific Islander patients**: Lowest absolute incidence (0.22%) but elevated SIR of 3.0. - These findings highlight significant racial and ethnic variations in PDAC risk following GNOD. 3. **Timing of PDAC Diagnosis**: - GNOD precedes clinical diagnosis of PDAC by an average interval of 8 months. - Over 60% of PDAC diagnoses occur within the first 12 months after GNOD onset. - Approximately 30% of PDAC cases are diagnosed within just 4 months of GNOD identification. - Nearly 80% of PDAC cases are diagnosed within 24 months of diabetes onset, emphasizing the narrow time window during which the risk is highest. 4. **Demographic Characteristics**: - The majority of PDAC cases occur in older adults, with a mean age of 71 years. - Men are disproportionately affected, accounting for 60% of PDAC diagnoses in the GNOD cohort. 5. **Active Surveillance and Early Detection**: - GNOD can be identified in real time through active surveillance of electronic health records and laboratory glycemic data. This approach may enable earlier identification of individuals at elevated risk for PDAC. - Understanding the biological mechanisms underlying diabetes in PDAC could help develop targeted early detection strategies for patients with new-onset glycemic abnormalities. 6. **Clinical Implications**: - GNOD represents a critical, time-limited window during which PDAC risk is at its peak. Early recognition of GNOD could improve outcomes by facilitating timely diagnostic evaluations for PDAC. - Since GNOD precedes PDAC diagnosis, healthcare providers should consider investigating pancreatic cancer in patients with unexplained new-onset diabetes, especially in older adults. ### Summary: New-onset diabetes (GNOD) is not only a metabolic condition but also a potential early indicator of pancreatic cancer, particularly PDAC. The short-term risk of PDAC following GNOD is significantly elevated, with racial and ethnic differences in incidence rates and risk levels. Active glycemic surveillance and early detection efforts are crucial to identifying individuals at high risk during the time-limited window when PDAC risk is highest. This research underscores the importance of integrating diabetes management with cancer screening protocols, especially for older adults and those with unexplained glycemic abnormalities.

High visceral adiposity and low skeletal muscle mass independently predict the development of acute cholecystitis in patients with gallstones: a retrospective cohort study

The retrospective cohort study you are referencing addresses the relationship between body composition and the risk of developing acute cholecystitis in patients with gallstones. The findings highlight that high visceral adiposity (excess visceral fat) and low skeletal muscle mass are independent predictors of acute cholecystitis, emphasizing the role of metabolic and inflammatory factors in disease progression. Below is a detailed breakdown of the study's key insights: ### 1. **Prediction Gap Addressed** - Traditional risk markers for acute cholecystitis, such as gallstone size or presence alone, are insufficient to predict which patients will progress to inflammation. This study shifts the focus to metabolic and body composition factors, providing a more comprehensive risk stratification. ### 2. **Limits of BMI** - Body mass index (BMI) is a crude measure of obesity and does not differentiate between types of body tissue (e.g., visceral fat, subcutaneous fat, muscle mass). Therefore, BMI alone cannot accurately predict susceptibility to acute cholecystitis. ### 3. **Role of Visceral Fat** - Visceral fat is metabolically active and contributes to a chronic pro-inflammatory state. This inflammatory priming makes the gallbladder more susceptible to exaggerated responses to triggers, such as gallstone obstruction, leading to acute cholecystitis. - Visceral fat is distinctly associated with disease risk, as opposed to subcutaneous fat, which does not have the same inflammatory properties. ### 4. **Importance of Sarcopenia (Low Skeletal Muscle Mass)** - Reduced skeletal muscle mass (sarcopenia) is not merely a marker of frailty but actively contributes to disease development. Muscle tissue plays a protective role by providing physiological resilience against inflammatory triggers. - Patients with low muscle mass may experience heightened vulnerability to metabolic and inflammatory complications, including acute cholecystitis. ### 5. **Independent Risk Factors** - Both high visceral fat and low skeletal muscle mass independently increase the likelihood of developing acute cholecystitis. These factors are not dependent on gender, gallstone size, or other traditional risk markers. ### 6. **Gallstones Alone Insufficient** - The study highlights that gallstones alone are not enough to cause acute cholecystitis. An adverse metabolic background, characterized by visceral adiposity and sarcopenia, is required to trigger the inflammatory process. ### 7. **Systemic Disease Concept** - Acute cholecystitis should be redefined as a metabolic-inflammatory complication rather than a localized biliary event. This systemic perspective broadens the understanding of the disease, linking it to underlying metabolic syndrome conditions such as hypertension and dyslipidemia. ### 8. **CT-Based Assessment** - Computed tomography (CT) imaging is a valuable tool for assessing body composition. It enables precise and reproducible measurement of visceral fat and skeletal muscle mass, which are critical for risk stratification. - The study emphasizes the use of body composition analysis at the L3 vertebral level, which is a validated standard for representing whole-body composition. ### 9. **Gender Independence** - The predictive value of visceral fat and muscle mass transcends sex-based differences. Men and women with unfavorable metabolic body composition phenotypes are equally at risk for acute cholecystitis. ### 10. **Preventive Medicine Potential** - Identifying patients with high visceral fat and low skeletal muscle mass early provides an opportunity for lifestyle interventions, such as tailored diet and exercise programs, to reduce the risk of disease progression. - These modifiable risk factors represent actionable targets for preventing acute cholecystitis in at-risk patients. ### 11. **Clinical Paradigm Shift** - The findings suggest a need to redefine acute cholecystitis as a metabolic-inflammatory complication rather than an isolated biliary obstruction caused by gallstones. This paradigm shift supports a more holistic approach to patient management, focusing on systemic health and body composition. ### 12. **Risk Stratification Tool** - CT-derived body composition analysis offers a practical and precise method to identify gallstone patients at high risk for acute cholecystitis. This tool can help clinicians prioritize closer monitoring and early intervention for these patients. ### 13. **Peripheral Monitoring Opportunity** - Patients identified with unfavorable body composition (high visceral fat and low skeletal muscle mass) may benefit from closer clinical surveillance to prevent disease progression and reduce the risk of complications. ### 14. **Inflammatory Priming** - Pro-inflammatory mediators released by visceral fat sensitize the gallbladder, increasing the likelihood of exaggerated inflammatory responses when gallstones obstruct the bile duct. ### 15. **Metabolic Syndrome Link** - The study reinforces the connection between acute cholecystitis and metabolic syndrome conditions, such as hypertension, dyslipidemia, and insulin resistance. These systemic factors further contribute to the inflammatory and metabolic background of the disease. ### Conclusion: This retrospective cohort study challenges traditional views of acute cholecystitis as a purely local biliary event and highlights the importance of systemic metabolic and inflammatory factors. High visceral adiposity and low skeletal muscle mass are independent predictors of disease development, providing actionable insights for early risk stratification, preventive interventions, and a shift in clinical management toward addressing the broader metabolic-inflammatory context of acute cholecystitis.

LAMS for EUS-guided drainage of pancreatic fluid collections

Lumen-apposing metal stents (LAMS) have emerged as a highly effective tool for endoscopic ultrasound (EUS)-guided drainage of pancreatic fluid collections (PFCs), such as pseudocysts and walled-off necrosis. This systematic review and meta-analysis evaluated three commonly used types of LAMS: Axios, Nagi, and Spaxus, focusing on their efficacy, safety, and clinical performance. ### Key Findings: #### **Technical Success:** All three LAMS demonstrated exceptional technical success rates: - **Axios:** 97.7% - **Nagi:** 96.9% - **Spaxus:** 98.2% This indicates that the placement of the stents is highly reliable across all types. #### **Clinical Success:** Clinical success rates, which reflect effective resolution of the pancreatic fluid collections, were also strong: - **Axios:** 90.9% - **Nagi:** 88.5% - **Spaxus:** 93.5% This highlights that all three stents are effective in achieving the desired therapeutic outcomes. #### **Adverse Events (AEs):** Safety profiles varied significantly among the stents. - **Axios:** Highest rate of total adverse events (20.4%). - **Nagi:** Moderate rate of adverse events (13.8%). - **Spaxus:** Lowest rate of adverse events (7.6%). #### **Bleeding:** Bleeding complications were an important safety consideration, with rates differing across stent types: - **Axios:** Highest bleeding rate (7.0%). - **Nagi:** Moderate bleeding rate (3.8%). - **Spaxus:** Lowest bleeding rate (1.8%). Moderate-to-severe bleeding occurred across all stent types but was notably less frequent with Spaxus. #### **Stent Migration:** Stent migration was another safety concern: - **Axios:** Rare (2.8%). - **Nagi:** Most common (7.8%). - **Spaxus:** Least common (0.9%). #### **Need for Endoscopic Necrosectomy:** The need for additional procedures, such as endoscopic necrosectomy to remove necrotic debris, differed significantly: - **Axios:** Highest necrosectomy requirement (54.5%). - **Nagi:** Lower requirement (16%). - **Spaxus:** Comparable to Nagi (19.9%). #### **Impact of PFC Type:** - Patients with **walled-off necrosis** experienced more frequent adverse events compared to those with **pseudocysts**. This reflects the complexity and severity of walled-off necrosis compared to simpler pseudocysts. ### Overall Assessment: While all three LAMS options provide excellent efficacy for draining pancreatic fluid collections, their safety profiles differ meaningfully. The **Spaxus stent** demonstrated the most favorable balance of high success rates and low complications, including minimal bleeding, stent migration, and adverse events. However, the choice of stent may depend on patient-specific factors, the type of PFC (pseudocyst vs. walled-off necrosis), and procedural considerations. ### Clinical Implications: - **Axios** may be preferred for cases where high clinical success is paramount, although its higher rates of adverse events and bleeding should be considered. - **Nagi** offers a moderate safety profile but has a higher risk of stent migration. - **Spaxus** stands out for its excellent safety profile, making it a strong choice for minimizing complications while maintaining high efficacy. In conclusion, LAMS are a transformative advancement in the management of pancreatic fluid collections, offering minimally invasive, highly effective treatment options with differences in safety outcomes that warrant careful consideration.

EUS-guided GJ in acute pancreatitis related Gastric Outlet obstruction

Endoscopic Ultrasound-Guided Gastrojejunostomy (EUS-GJ) is an innovative, minimally invasive procedure that has gained traction as a treatment for gastric outlet obstruction (GOO) due to duodenal stenosis caused by acute pancreatitis. Acute pancreatitis can lead to inflammation and scarring in the duodenum, resulting in mechanical obstruction that prevents food passage from the stomach to the intestines. EUS-GJ offers a safe and effective alternative to traditional surgery for managing this condition. Below is a detailed explanation of why EUS-GJ is required and the technical challenges associated with the procedure: ### **Why EUS-GJ is Required** 1. **Minimally Invasive Alternative to Surgery**: - Traditional surgical gastrojejunostomy involves open or laparoscopic surgery, which can be associated with significant morbidity, longer recovery times, and increased risks in patients with acute pancreatitis. EUS-GJ provides a less invasive option that reduces these risks while achieving similar outcomes. 2. **Bypassing the Obstructed Duodenum**: - Acute pancreatitis-related duodenal stenosis can lead to severe symptoms such as nausea, vomiting, and an inability to tolerate oral intake. EUS-GJ bypasses the obstructed duodenum by creating a direct connection between the stomach and the jejunum (a part of the small intestine), restoring gastrointestinal continuity and allowing food passage. 3. **High Success Rates**: - The study reported a technical success rate of 92.3% and clinical success rate of 87.2%, demonstrating the effectiveness of EUS-GJ in relieving symptoms of GOO and improving oral intake. 4. **Durability and Long-Term Relief**: - Among patients with long-term follow-up (median 23 months), EUS-GJ showed good durability, with only a small number requiring reintervention. This makes it a reliable option for managing chronic GOO caused by acute pancreatitis. 5. **Low Complication Rates**: - Compared to surgical alternatives, EUS-GJ has a low rate of adverse events. In the study, only one significant complication (a gastrocolic fistula) was reported, and it did not lead to major clinical issues. ### **Technical Difficulties in EUS-GJ** EUS-GJ is a technically complex procedure that requires expertise in advanced endoscopy and familiarity with the use of lumen-apposing metal stents (LAMS). Some of the key technical challenges include: 1. **Anatomical Limitations**: - In some patients, the distance between the stomach and the small bowel may be too great, making it difficult to deploy the stent effectively. This was a limitation in three patients in the study, leading to procedural failure. 2. **Safe Puncture Window**: - The procedure relies on identifying a safe puncture site between the stomach and jejunum using endoscopic ultrasound. In cases where the anatomy does not allow for a clear puncture window, the procedure cannot be performed. 3. **Stent Deployment**: - Precise deployment of the lumen-apposing metal stent is critical for the success of the procedure. Misplacement or migration of the stent can lead to complications such as leakage, infection, or fistula formation. 4. **Risk of Adverse Events**: - Although the overall rate of complications is low, potential risks include bleeding, perforation, stent migration, or the formation of abnormal connections (e.g., gastrocolic fistula). These complications require careful monitoring and management. 5. **Need for Reintervention**: - In some cases, patients may require reintervention due to stent-related issues or recurrence of symptoms. The study reported that four patients needed reintervention during follow-up. 6. **Learning Curve**: - EUS-GJ requires advanced technical skills and experience with endoscopic ultrasound and stent placement. The procedure may be challenging for less experienced endoscopists, limiting its availability in some centers. ### **Conclusion** EUS-GJ is a groundbreaking procedure for managing gastric outlet obstruction caused by acute pancreatitis. It offers a safe, effective, and durable alternative to surgery, with high success rates and low complication rates. However, its technical complexity and anatomical limitations highlight the importance of careful patient selection and the need for skilled operators. As the procedure becomes more widely adopted, ongoing research and training will be critical to further improving outcomes and expanding its accessibility.

EUS-guided ethanol injections of small pancreatic NET

Endoscopic ultrasonography-guided ethanol injection (EUS-EI) is emerging as a promising, minimally invasive treatment for small pancreatic neuroendocrine tumors (PNENs), particularly for patients seeking alternatives to surgery. This approach involves using endoscopic ultrasound to guide the precise injection of ethanol into the tumor, inducing its ablation. The procedure has shown high efficacy in achieving complete tumor ablation and demonstrates a strong safety profile, with minimal risk of severe complications such as pancreatic fistulas or adverse events. Additionally, it appears to preserve pancreatic endocrine function, as most patients did not experience new or worsening diabetes after the procedure. EUS-EI offers a less invasive option compared to traditional surgical methods, making it a potentially suitable choice for patients with small, low-grade PNENs. This treatment is particularly beneficial for carefully selected patients who prioritize reduced recovery time and lower procedural risks.

Surveillance of Primary Sclerosing Cholangitis - EASL Guideline

Surveillance for Primary Sclerosing Cholangitis (PSC) is critical due to the high risk of hepatobiliary complications, including cholangiocarcinoma (CCA), gallbladder cancer, and liver failure, all of which significantly impact patient outcomes. The European Association for the Study of the Liver (EASL) provides guidelines to optimize the management of PSC, including recommendations for surveillance strategies aimed at early detection of complications and timely intervention. ### Why is Surveillance Necessary for PSC? 1. **High Risk of Cancer**: PSC is strongly associated with an elevated risk of cholangiocarcinoma, with an incidence of 0.5–1.5% per year in affected individuals. Additionally, the risk of gallbladder cancer and hepatocellular carcinoma (HCC) is also increased. 2. **Asymptomatic Progression**: PSC often progresses silently, with many patients remaining asymptomatic until advanced stages of disease or cancer development. Surveillance enables early detection of complications. 3. **Lack of Reliable Biomarkers**: There are no highly sensitive or specific tumor markers for PSC-associated cancers, such as CCA. CA19-9, a commonly used marker, has limited reliability and may lead to false positives or negatives. 4. **Improved Prognosis with Early Detection**: Early identification of disease progression or malignancy can lead to timely interventions, including liver transplantation, which may improve survival rates. ### EASL Guidelines on PSC Surveillance The EASL guidelines emphasize the importance of regular and structured surveillance for PSC patients to monitor for disease progression and associated complications. Key recommendations include: 1. **Regular Clinical Assessments**: - Patients should undergo regular clinical evaluations, including liver function tests, to monitor disease progression and assess for symptoms suggestive of complications such as biliary strictures or infections. 2. **Imaging Surveillance**: - **Magnetic Resonance Imaging (MRI) with Magnetic Resonance Cholangiopancreatography (MRCP)**: EASL recommends annual or biennial MRI/MRCP as the preferred imaging modality for PSC surveillance. This approach provides detailed visualization of the biliary tree and liver parenchyma, aiding in the detection of biliary strictures, CCA, or other abnormalities. - **Ultrasound**: While not as detailed as MRI/MRCP, regular ultrasound may be used to screen for gallbladder polyps or masses, which could indicate gallbladder cancer. 3. **Endoscopic Retrograde Cholangiopancreatography (ERCP)**: - ERCP should not be used routinely for surveillance due to its invasive nature and associated risks (e.g., pancreatitis, infections). However, it is recommended in cases where there are clinical or imaging findings suggestive of biliary obstruction, strictures, or malignancy. - In certain high-risk cases, scheduled ERCP with brush cytology and/or biopsies may be considered for more intensive surveillance, as highlighted in the study provided. 4. **Biomarker Monitoring**: - **CA19-9**: Serum CA19-9 levels may be measured annually, but clinicians should interpret results with caution due to the risk of false positives (e.g., due to cholangitis or other benign conditions) and false negatives (e.g., in patients who are non-secretors of CA19-9). - Other biomarkers, such as liver enzymes (alkaline phosphatase, bilirubin), should also be monitored regularly as they may indicate disease progression or complications. 5. **Colorectal Cancer Screening**: - PSC is closely linked with inflammatory bowel disease (IBD), particularly ulcerative colitis, which increases the risk of colorectal cancer. EASL recommends annual or biennial colonoscopy for PSC patients with IBD, starting at the time of PSC diagnosis, regardless of the duration of IBD. 6. **Gallbladder Surveillance**: - Gallbladder polyps >8 mm in size warrant surgical removal due to the high risk of malignancy in PSC patients. - Annual ultrasound imaging is recommended to monitor for gallbladder abnormalities. 7. **Liver Transplantation Consideration**: - Surveillance plays a critical role in identifying patients who may benefit from liver transplantation. Early referral for transplantation evaluation is recommended for patients with decompensated cirrhosis, recurrent cholangitis, or early-stage CCA. ### Insights from the Study in Context The study you provided highlights the potential benefits of scheduled ERCP as a surveillance strategy for PSC patients. While EASL guidelines currently favor MRI/MRCP as the primary imaging modality for routine surveillance due to its non-invasive nature, the study suggests that scheduled ERCP combined with individualized risk assessment may provide better outcomes in terms of earlier detection of disease progression and reduced cumulative incidence of adverse events. However, the invasive nature and potential complications of ERCP mean that its routine use for all PSC patients is not currently endorsed by EASL; instead, it is reserved for cases with specific clinical indications. ### Summary EASL guidelines prioritize non-invasive imaging (e.g., MRI/MRCP) and regular biomarker monitoring for PSC surveillance, while reserving invasive procedures like ERCP for specific clinical scenarios. The goal of surveillance is to detect complications such as cholangiocarcinoma, biliary strictures, and liver decompensation early, enabling timely intervention and improving long-term outcomes. The study findings suggest that scheduled ERCP may offer additional benefits in certain high-risk patients, which could inform future updates to surveillance guidelines.

Optimal timing for LAMS removal after EUS-guided drainage of PFC

The optimal timing for lumen-apposing metal stent (LAMS) removal after EUS-guided drainage of pancreatic fluid collections (PFCs) does not necessarily depend on a fixed timeline, such as early removal within 3–4 weeks. A systematic review and meta-analysis of 8 studies involving 1820 patients found no significant difference in adverse events (AEs) between early and late stent removal. The pooled risk ratio for AEs was 1.03, indicating comparable safety outcomes regardless of removal timing. Additionally, a sensitivity analysis using a strict 4-week cut-off confirmed these findings. Prolonged stent placement has been associated with complications like bleeding, buried stents, and infection, but early removal does not appear to reduce these risks. The study suggests that removal timing should be guided by clinical judgment rather than a universal early-removal policy. Factors such as patient stability, imaging findings, and individual circumstances should dictate the decision, supporting a case-by-case approach rather than adhering to a rigid timeline.

Portal versus peripheral circulating tumor cells in PDAC

The study you referenced investigates the differences between portal and peripheral circulating tumor cells (CTCs) in pancreatic ductal adenocarcinoma (PDAC) and their prognostic value. Here’s a detailed breakdown of the findings and their implications: ### Background: - Pancreatic tumors drain into the portal venous system before entering systemic circulation. This suggests that CTCs collected from the portal vein may better reflect tumor biology, early micrometastasis, and aggressiveness compared to CTCs collected from peripheral blood. - The study aimed to determine whether portal vein CTCs provide superior prognostic information compared to peripheral CTCs in patients with stage I–III PDAC. ### Methodology: - **Patient Cohort**: A prospective cohort of 35 patients with stage I–III PDAC was studied. - **Blood Sampling**: - **Portal Venous Blood**: Obtained using endoscopic ultrasound–guided techniques. - **Peripheral Blood**: Drawn conventionally. - **CTC Identification**: CTCs were detected using antibodies targeting EpCAM and mucin-1. - **Analysis**: CTC counts were correlated with tumor characteristics, survival outcomes, and prognostic significance. ### Key Findings: 1. **Detection Rates**: - Portal venous blood showed a higher detection rate of CTCs (94.3%) compared to peripheral blood (82.9%). - This indicates that portal blood more reliably captures CTCs, likely because pancreatic tumors drain directly into the portal venous system. 2. **Correlation with Tumor Characteristics**: - Portal CTC levels strongly correlated with aggressive tumor features, including: - Tumor size ≥5 cm. - Vascular invasion. - Lymph node metastasis. - Stage III disease. - Peripheral CTCs did not show similar associations with these aggressive tumor characteristics. - This suggests that portal CTCs better reflect the true biology and local spread of the tumor. 3. **Prognostic Value**: - **Portal CTCs**: - Patients with portal CTC counts ≥8 had significantly shorter survival (median of 6.1 months) compared to those with counts <8 (19 months). - **Peripheral CTCs**: - Patients with peripheral CTC counts ≥3 also had shorter survival (4.6 months) compared to those with counts <3 (14.2 months). - Both portal and peripheral CTCs were independent predictors of mortality in multivariable analyses. - However, portal CTCs were more effective in capturing tumor aggressiveness and locoregional metastatic potential. 4. **Survival Outcomes**: - Elevated CTC counts in both portal and peripheral blood were associated with worse survival. - However, portal CTCs provided stronger prognostic information, making them a more powerful biomarker for early-stage to locally advanced PDAC. ### Clinical Implications: - **Prognostic Biomarker**: Portal CTCs are a more reliable and robust biomarker for predicting prognosis in PDAC compared to peripheral CTCs. - **Early Detection of Aggressiveness**: Portal CTCs may help identify patients with aggressive tumor features and early micrometastasis, allowing for better stratification and treatment planning. - **Potential for Personalized Therapy**: Monitoring portal CTC levels could guide treatment decisions, such as the need for more aggressive therapy in patients with high portal CTC counts. ### Conclusion: - While both portal and peripheral CTCs predict worse survival outcomes in PDAC, portal CTCs are superior in capturing tumor aggressiveness, locoregional spread, and early micrometastasis. This positions portal venous CTCs as a more powerful and clinically relevant prognostic biomarker for patients with stage I–III PDAC.

Risk of Pancreatic Cancer in Patients With Chronic Pancreatitis

Patients with chronic pancreatitis face a significantly increased risk of developing pancreatic cancer compared to individuals without pancreatitis. According to the systematic review and meta-analysis, chronic pancreatitis is associated with a hazard ratio (HR) of 7.82 (95% CI: 5.25–11.65), indicating that the risk is nearly eight times greater for these patients. Chronic pancreatitis poses a higher risk than acute pancreatitis, which has an HR of 3.54 (95% CI: 1.84–6.80). The stronger association with chronic pancreatitis highlights the role of long-term inflammation in the development of pancreatic cancer. The study also found that the risk is particularly elevated for pancreatic ductal adenocarcinoma (PDAC) (HR: 6.57, 95% CI: 5.31–8.14) and intraductal papillary mucinous neoplasms (IPMN) (HR: 17.19, 95% CI: 8.83–33.46). These findings suggest that chronic pancreatitis may play a critical role in the development of both malignant and precancerous pancreatic lesions. Given the significant risk, patients with chronic pancreatitis should be considered a high-risk group for pancreatic cancer. This underscores the need for further research into cost-effective screening and monitoring strategies to detect pancreatic cancer or precancerous lesions early in this vulnerable population.

Risk factor analysis for survival prediction in severe acute pancreatitis

Risk factor analysis for survival prediction in severe acute pancreatitis (SAP) focuses on identifying key clinical and biochemical parameters that influence patient outcomes. In the specific context of obese patients with SAP, the study highlighted the following points: ### 1. **Objective of Risk Factor Analysis**: - The research aimed to develop a specialized predictive tool (nomogram) for assessing mortality risk in obese SAP patients, as existing tools lacked specificity for this high-risk group. ### 2. **Methodology**: - The study analyzed data from 394 obese SAP patients (341 survivors, 53 deceased) collected between 2016 and 2023. - Risk factors were identified using Least Absolute Shrinkage and Selection Operator (LASSO) regression, which is a statistical method to select the most relevant predictors. - These factors were incorporated into a multivariable logistic regression model to construct the nomogram. ### 3. **Key Risk Factors Identified**: - **Age**: Older patients were found to have a higher risk of mortality, likely due to reduced physiological reserves and increased comorbidities. - **Total Bilirubin**: Elevated bilirubin levels suggest liver dysfunction or biliary complications, which can exacerbate SAP severity. - **Blood Urea Nitrogen (BUN)**: High BUN levels are indicative of renal dysfunction and dehydration, both of which are associated with worse outcomes in SAP. - **Potassium Levels**: Abnormal potassium levels can lead to cardiac complications and are markers of electrolyte imbalance, a common feature in SAP. - **Activated Partial Thromboplastin Time (aPTT)**: Prolonged aPTT is a sign of coagulation abnormalities, which are often seen in severe inflammatory states like SAP. - **Malignancy**: The presence of cancer significantly increases the risk of mortality, possibly due to compromised immunity and overall health status. ### 4. **Performance of the Predictive Model**: - The nomogram developed using these risk factors demonstrated superior predictive accuracy compared to traditional scoring systems like the Sequential Organ Failure Assessment (SOFA) score (P=0.011). - It showed strong discrimination (ability to distinguish between survivors and non-survivors), calibration accuracy (alignment of predicted and actual outcomes), and clinical utility (usefulness in practical decision-making). ### 5. **Clinical Implications**: - The nomogram provides a visual, user-friendly tool for clinicians to assess mortality risk in obese SAP patients. - It enables better risk stratification, allowing for personalized management strategies, early intervention, and resource allocation to improve survival outcomes. - By focusing on specific risk factors relevant to obese patients, the tool addresses the unique challenges posed by this subgroup, which is often associated with worse outcomes in SAP. ### 6. **Significance of Risk Factor Analysis**: - Identifying and understanding risk factors helps in tailoring treatment approaches, such as aggressive fluid resuscitation, nutritional support, or early intervention for organ dysfunction. - It also aids in counseling patients and families about prognosis and guiding clinical decisions regarding ICU admission or advanced therapies. In summary, risk factor analysis for survival prediction in SAP, especially in obese patients, is critical for improving outcomes. The development of the nomogram based on key predictors like age, bilirubin, BUN, potassium, aPTT, and malignancy provides a robust tool for clinicians to manage this complex condition effectively.

Biomarker testing in biliary tract cancer

Biomarker testing in biliary tract cancer (BTC) has emerged as a critical tool for guiding precision therapy, improving treatment outcomes, and understanding the molecular landscape of this heterogeneous disease. Below is a detailed overview of biomarker testing in BTC based on the context provided: ### Importance of Biomarker Testing in BTC Biomarker testing, particularly through next-generation sequencing (NGS), is essential for identifying actionable genomic alterations (GA) that can be targeted with precision therapies. BTC is a rare and aggressive cancer with limited treatment options, and molecular profiling enables clinicians to identify specific genetic mutations or alterations that can inform personalized treatment strategies. ### Implementation of NGS in BTC 1. **Study Overview**: A large multicenter study involving 1,521 BTC patients across 18 centers in Germany and Austria analyzed the implementation of NGS-based testing in clinical practice. 2. **Testing Platforms**: Twenty-four different sequencing panels were used across centers, revealing significant variability in assay design, gene coverage, and reporting. Despite this variability, broad sequencing assays captured a similar number of actionable genomic alterations, indicating that essential targets are generally well-represented across platforms. 3. **Standardization Challenges**: A comparison between FoundationOne CDx and TruSight Oncology 500 demonstrated discrepancies in reported alterations due to differences in panel coverage and analysis pipelines. This highlights the need for harmonized biomarker testing protocols across Europe to ensure consistent clinical interpretations. ### Key Findings from Biomarker Testing in BTC 1. **Most Frequent Mutations**: The most commonly detected mutations were TP53 and KRAS, followed by FGFR2, IDH1, and ERBB2 (HER2), which showed subtype-specific distribution across intrahepatic and extrahepatic tumors. 2. **Subtype Distribution**: - **Intrahepatic cholangiocarcinoma (iCCA)**: Comprising 65% of cases, iCCA was enriched with FGFR2 fusions and IDH1 mutations. - **Extrahepatic tumors**: KRAS and ERBB2 alterations were more frequent in extrahepatic cholangiocarcinoma and gallbladder cancers. 3. **Actionable Alterations**: Approximately 40% of BTC patients harbored actionable mutations, with key targets including: - FGFR2 alterations (14%) - HER2 amplifications (3%) - BRAFV600E mutations (2%) - IDH1 mutations ### Clinical Impact of Biomarker Testing 1. **Targeted Therapy Utilization**: Despite the identification of actionable alterations in 40% of patients, only 13.5% (205 patients) actually received genotype-matched targeted therapy, highlighting a significant implementation gap between testing and treatment. 2. **Survival Benefits**: Patients who received targeted therapies based on biomarker testing had significantly improved outcomes: - Median overall survival (mOS) of 31.8 months with targeted therapy versus 22.8 months without targeted therapy (p<0.01). - FGFR2 alterations treated with FGFR inhibitors led to an mOS exceeding 48 months from diagnosis. - HER2-amplified tumors showed poor prognosis without targeted therapy (10.5 months mOS) but improved markedly (27.6 months) with HER2-directed agents. - BRAFV600E mutations were associated with a poor prognosis without treatment (7.4 months mOS) but demonstrated significant improvement (31.8 months) under targeted therapy. 3. **Other Findings**: - IDH1 mutations were not independently prognostic, but treatment with ivosidenib showed a trend toward improved survival in real-world settings. - BRCA1/2 mutations may benefit from PARP inhibitors or platinum-based therapies, as some patients achieved long-term survival. - Negative prognostic markers included TP53 mutations, MTAP deletions, and CDKN2A/B deletions, which were associated with worse survival. - Positive prognostic markers included BAP1 alterations, which correlated with improved survival (31.2 months vs. 24.6 months) and often co-occurred with FGFR2 fusions. ### Advances and Challenges in Biomarker Testing 1. **Improved Testing Timelines**: The median time from diagnosis to molecular testing decreased significantly from 107 days (before 2021) to 37 days (after 2021), reflecting better integration of molecular profiling into clinical workflows. 2. **Need for Standardization**: The study emphasizes the importance of standardized, comprehensive molecular profiling to reduce discrepancies across testing platforms and ensure consistent clinical interpretations. 3. **Real-World Integration**: Despite advances in biomarker testing, the low rate of targeted therapy utilization underscores the need for improved access to precision treatments and better alignment between testing results and clinical decision-making. ### Core Conclusion Biomarker testing, particularly through NGS, is a transformative approach for BTC management. By identifying actionable genomic alterations, clinicians can tailor treatments to improve patient outcomes. However, challenges such as variability in testing platforms, delays in testing, and limited access to targeted therapies must be addressed. The study advocates for harmonized biomarker testing protocols and broader integration of molecular profiling into routine clinical practice to maximize the benefits of precision medicine for BTC patients.

Acalculus Biliary Pain and Acalculus Cholecystitis

**Acalculus Biliary Pain and Acalculus Cholecystitis** Both acalculus biliary pain and acalculus cholecystitis are conditions associated with the gallbladder but differ in their presentation, underlying mechanisms, and clinical significance. Below is a detailed breakdown: --- ### **Acalculus Biliary Pain** Acalculus biliary pain refers to biliary-type pain that occurs in the absence of gallstones or other structural abnormalities in the gallbladder. It is a functional disorder and is often categorized under **functional gallbladder disorders** or **functional biliary disorders**. #### **Key Features:** 1. **Symptoms:** - Recurrent episodes of right upper quadrant or epigastric pain. - Pain may radiate to the back or shoulder. - Often associated with nausea and vomiting. - Pain is typically postprandial, especially after fatty meals, but can occur without food triggers. - Episodes may last for 30 minutes or more. 2. **Pathophysiology:** - Dysfunction of the gallbladder or sphincter of Oddi without structural abnormalities. - Impaired gallbladder motility or hypersensitivity of the biliary tract. 3. **Diagnosis:** - Exclusion of structural abnormalities via imaging (e.g., ultrasound, CT scan, MRI). - Normal liver function tests, bilirubin, and amylase/lipase levels. - **Hepatobiliary iminodiacetic acid (HIDA) scan** with cholecystokinin (CCK) stimulation may show reduced gallbladder ejection fraction (<35%) indicating dysfunction. 4. **Management:** - Lifestyle modifications (low-fat diet). - Pain management (analgesics or antispasmodics). - In selected cases, **cholecystectomy** may be performed if gallbladder dysfunction is confirmed and symptoms are debilitating. --- ### **Acalculus Cholecystitis** Acalculus cholecystitis is an **inflammatory condition** of the gallbladder that occurs **without the presence of gallstones**. It is more common in critically ill or hospitalized patients and has a higher morbidity than calculous cholecystitis. #### **Key Features:** 1. **Symptoms:** - Acute right upper quadrant pain. - Fever and signs of systemic inflammation. - Nausea and vomiting. - May progress to sepsis or gallbladder necrosis if untreated. 2. **Risk Factors:** - Prolonged fasting or total parenteral nutrition (TPN). - Critical illness (e.g., trauma, burns, sepsis, major surgery). - Immunosuppression. - Diabetes mellitus. - Vasculitis or ischemia leading to poor gallbladder perfusion. 3. **Pathophysiology:** - Gallbladder stasis due to fasting or immobility leads to bile inspissation and inflammation. - Ischemia of the gallbladder wall due to hypoperfusion in critically ill patients. - Secondary bacterial infection may develop (e.g., E. coli, Klebsiella, Enterococcus). 4. **Diagnosis:** - **Ultrasound**: Thickened gallbladder wall (>3 mm), pericholecystic fluid, and absence of gallstones. - **CT scan**: Can show gallbladder distension, wall thickening, or necrosis. - Elevated inflammatory markers (CRP, leukocytosis). - Blood cultures may be positive in septic patients. 5. **Management:** - Supportive care: IV fluids, broad-spectrum antibiotics targeting gram-negative and anaerobic organisms. - Pain management. - **Percutaneous cholecystostomy**: Drainage of the gallbladder for critically ill patients who cannot undergo surgery. - **Cholecystectomy**: Definitive treatment when the patient is stable enough for surgery. 6. **Complications:** - Gallbladder perforation. - Peritonitis. - Sepsis. - Abscess formation. --- ### **Comparison Table** | Feature | Acalculus Biliary Pain | Acalculus Cholecystitis | |-----------------------------|--------------------------------------------|------------------------------------------| | **Underlying Mechanism** | Functional gallbladder or sphincter dysfunction. | Inflammation due to stasis or ischemia. | | **Gallstones** | Absent | Absent | | **Symptoms** | Chronic episodic pain, nausea, postprandial discomfort. | Acute pain, fever, systemic signs. | | **Risk Factors** | None specific; idiopathic. | Critical illness, fasting, TPN, trauma. | | **Diagnosis** | Normal imaging, abnormal HIDA scan. | Imaging shows thickened wall, fluid. | | **Treatment** | Lifestyle changes, cholecystectomy if needed. | Antibiotics, cholecystostomy, surgery. | --- ### **Key Points for PG Students:** 1. Always differentiate between functional biliary pain and acute inflammatory conditions. 2. Acalculus cholecystitis is a medical emergency in critically ill patients, requiring prompt diagnosis and management to prevent complications. 3. Acalculus biliary pain is a less urgent condition but can significantly impact quality of life; diagnosis relies on exclusion and functional imaging. 4. Familiarize yourself with diagnostic tools like HIDA scans, ultrasound findings, and CT imaging for gallbladder assessment. 5. Multidisciplinary management (gastroenterology, surgery, radiology) is often required for acalculus cholecystitis, especially in critically ill patients. Understanding these conditions is crucial for timely intervention and improving patient outcomes.

SBRT versus chemoradiation after induction chemotherapy in locally advanced pancreatic cancer

The study described compares the outcomes of **Stereotactic Body Radiation Therapy (SBRT)** versus **Conventional Chemoradiation (CRT)** following induction chemotherapy in patients with **Locally Advanced Pancreatic Cancer (LAPC)** and **Borderline Resectable Pancreatic Cancer (BRPC)**. Below is a detailed explanation of the findings and the concepts involved: --- ### **Key Findings from the Study** 1. **Resectability**: - Resectability was achieved in **15% of patients**, and all of these were from the SBRT arm. Importantly, all patients who became resectable were initially diagnosed with LAPC. - CRT did not lead to any cases of resectability. 2. **Survival Outcomes**: - Patients treated with SBRT had a **mean overall survival (OS)** of **21.8 months** compared to **13 months** for CRT. - SBRT also resulted in a longer **local progression-free survival (LPFS)** (14 months vs. 8.6 months with CRT). - The **one-year overall survival rate** was significantly higher with SBRT (**80%**) compared to CRT (**45%**). 3. **Toxicity and Quality of Life**: - SBRT showed **no grade 3 or 4 toxicities**, whereas CRT was associated with higher toxicity levels. - Patients in the SBRT group reported better **quality of life (QoL)** scores compared to those receiving CRT. 4. **Immune and Inflammatory Markers**: - Lower **neutrophil-to-lymphocyte ratio (NLR)** and **platelet-to-lymphocyte ratio (PLR)** were associated with improved survival outcomes, suggesting these markers may be predictive of better treatment responses. --- ### **Definitions and Concepts** #### **Locally Advanced Pancreatic Cancer (LAPC)**: - LAPC refers to pancreatic cancer that has spread to nearby structures (e.g., blood vessels), making surgical removal (resection) impossible or highly challenging. It has not metastasized to distant organs but is confined to the pancreas and surrounding areas. #### **Borderline Resectable Pancreatic Cancer (BRPC)**: - BRPC is a stage of pancreatic cancer where the tumor is in close proximity to major blood vessels, making surgical resection technically possible but with a high risk of incomplete removal. Neoadjuvant (pre-surgical) treatments like chemotherapy or radiation are often used to shrink the tumor and improve the chances of a successful surgery. #### **Induction Chemotherapy**: - Induction chemotherapy refers to the initial phase of systemic treatment aimed at reducing tumor size, controlling disease progression, and improving the likelihood of subsequent treatments (e.g., radiation or surgery). In this study, patients received either: - **Modified FOLFIRINOX**: A combination of chemotherapy drugs (5-FU, leucovorin, irinotecan, and oxaliplatin) commonly used for aggressive pancreatic cancer. - **Gemcitabine with nab-paclitaxel**: Another chemotherapy regimen used for pancreatic cancer. #### **Stereotactic Body Radiation Therapy (SBRT)**: - SBRT is a highly precise form of radiation therapy that delivers high doses of radiation to the tumor in a few sessions (typically 5–6 fractions in this study). It minimizes damage to surrounding healthy tissues and is associated with fewer side effects than conventional radiation. #### **Conventional Chemoradiation (CRT)**: - CRT combines standard radiation therapy with chemotherapy (in this study, Capecitabine was used as the radiosensitizing agent). It is typically delivered over a longer duration (e.g., 25 fractions in this study) and is associated with higher toxicity compared to SBRT. --- ### **Comparison of SBRT vs. CRT in LAPC** #### **Advantages of SBRT**: - **Higher Resectability Rates**: SBRT enabled some patients with LAPC to achieve resectability, whereas CRT did not. - **Improved Survival**: SBRT significantly extended overall survival (21.8 months vs. 13 months with CRT) and local progression-free survival (14 months vs. 8.6 months with CRT). - **Better Quality of Life**: Patients receiving SBRT reported improved QoL scores. - **Lower Toxicity**: SBRT was associated with no grade 3 or 4 toxicities, making it a safer option compared to CRT. #### **Limitations of CRT**: - CRT showed lower efficacy in terms of resectability and survival outcomes. - Higher toxicity levels were observed, which could negatively impact patient quality of life. --- ### **Conclusion** The study suggests that **SBRT following induction chemotherapy** is superior to **CRT** for patients with LAPC and BRPC in terms of: - **Resectability**: SBRT increases the likelihood of converting unresectable tumors to resectable ones. - **Survival**: SBRT provides better overall survival and local progression-free survival. - **Quality of Life and Safety**: SBRT is associated with fewer toxicities and improved patient-reported outcomes. However, these findings are preliminary due to the small sample size (20 patients) and single-institution nature of the trial. Larger, multicenter randomized trials are needed to confirm these results and establish SBRT as a standard of care for LAPC and BRPC.

Circulating tumor DNA and extrahepatic Cholangiocarcinoma

**Circulating Tumor DNA (ctDNA):** Circulating tumor DNA (ctDNA) refers to fragments of DNA that are shed into the bloodstream by tumor cells. These DNA fragments carry tumor-specific genetic mutations, making them a valuable biomarker for detecting and monitoring cancer. ctDNA is a component of cell-free DNA (cfDNA), which includes DNA released by normal cells as well. The presence of ctDNA in the blood provides critical insights into the molecular characteristics of the tumor, including genetic alterations, tumor burden, and residual disease after treatment. Key features of ctDNA: - **Tumor-Specific Mutations:** ctDNA contains somatic mutations unique to the tumor, which can be identified using advanced sequencing techniques. - **Non-Invasive Biomarker:** ctDNA is obtained through a simple blood draw, making it a minimally invasive method for cancer monitoring compared to tissue biopsies. - **Dynamic Monitoring:** ctDNA levels can be monitored over time to assess treatment response, detect minimal residual disease (MRD), and predict recurrence. - **Lead Time Advantage:** ctDNA often detects cancer recurrence earlier than imaging or traditional biochemical markers like CA19-9 or CEA, providing a lead time of several months. **Role of ctDNA in Extrahepatic Cholangiocarcinoma (eCCA):** Extrahepatic cholangiocarcinoma (eCCA) is a type of bile duct cancer that arises outside the liver. It is an aggressive malignancy with poor prognosis and high recurrence rates even after complete surgical resection. Current biomarkers like CA19-9 and CEA have limited accuracy in predicting outcomes, highlighting the need for more precise tools like ctDNA. The study provided several key insights into the role of ctDNA in eCCA: 1. **Prognostic Value:** ctDNA positivity after surgery, before or during adjuvant chemotherapy (ACT), strongly predicts recurrence and survival outcomes. Persistent ctDNA or rising levels during ACT are associated with worse disease-free survival (DFS) and overall survival (OS). 2. **Early Detection of Residual Disease:** ctDNA detected after surgery but before ACT identifies patients with molecular residual disease (MRD). These patients have a significantly higher recurrence risk and shorter DFS compared to ctDNA-negative individuals. 3. **Monitoring During ACT:** ctDNA positivity at 12 and 24 weeks during ACT is a powerful indicator of poor prognosis, independent of chemotherapy regimen or tumor location. 4. **Dynamic Changes:** Patients whose ctDNA status converts from positive to negative during ACT have outcomes comparable to those who are persistently ctDNA-negative, suggesting they benefit most from therapy. Conversely, persistent positivity or conversion from negative to positive indicates the need for alternative or intensified treatments. 5. **Lead Time Over Imaging:** ctDNA positivity precedes radiologic recurrence by an average of 174–222 days, enabling earlier intervention and potentially improving outcomes. 6. **Superiority to Traditional Biomarkers:** ctDNA outperforms CA19-9 and CEA in predicting recurrence and survival, offering higher sensitivity and specificity for molecular relapse monitoring. **Prevalence and Clinical Characteristics of Extrahepatic Cholangiocarcinoma:** Extrahepatic cholangiocarcinoma accounts for approximately 50–60% of all cholangiocarcinoma cases. It arises from the bile ducts outside the liver, including the perihilar region (near the liver hilum) or distal bile ducts (closer to the pancreas). Key clinical features include: - **Incidence:** Cholangiocarcinoma is rare, with an overall annual incidence of 1–2 cases per 100,000 people globally. eCCA is more common in older adults, with peak incidence between 60–70 years. - **Aggressive Nature:** eCCA is characterized by rapid progression, high recurrence rates after surgery, and poor long-term survival outcomes. - **Risk Factors:** Risk factors include primary sclerosing cholangitis (PSC), chronic biliary inflammation, liver fluke infections, bile duct cysts, and exposure to carcinogens. - **Symptoms:** Patients often present with jaundice, abdominal pain, weight loss, and bile duct obstruction, which may delay diagnosis until advanced stages. - **Treatment:** Surgery remains the primary curative option for resectable eCCA, but recurrence rates are high even after complete resection. Adjuvant chemotherapy (ACT) is often administered to reduce recurrence risk, though its effectiveness varies. **Clinical Implications of ctDNA in eCCA:** The study findings demonstrate that ctDNA is a powerful tool for managing eCCA. Its applications include: - **Risk Stratification:** ctDNA positivity can identify patients at higher risk of recurrence, enabling personalized treatment planning. - **Therapeutic Monitoring:** Longitudinal ctDNA monitoring can assess the effectiveness of adjuvant chemotherapy and guide decisions on treatment modification or escalation. - **Early Intervention:** ctDNA's lead time over imaging allows clinicians to detect relapse earlier and initiate salvage therapies before clinical or radiologic evidence of progression. - **Personalized Medicine:** Persistently ctDNA-positive patients may benefit from more aggressive or alternative therapies, while ctDNA-negative patients can avoid unnecessary treatments. **Conclusion:** Circulating tumor DNA (ctDNA) is a revolutionary biomarker in the management of extrahepatic cholangiocarcinoma (eCCA). Its ability to detect residual disease, predict recurrence, and monitor treatment response provides a non-invasive and highly sensitive approach to improving outcomes in this aggressive cancer. By integrating ctDNA into clinical practice, clinicians can achieve more personalized, dynamic, and effective care for eCCA patients. However, further large-scale studies are needed to validate these findings and standardize ctDNA testing protocols.

Dynamic lipase trajectory patterns and in-hospital mortality in acute pancreatitis:

Dynamic lipase trajectory patterns and in-hospital mortality in acute pancreatitis (AP) provide valuable insights into the progression of the disease and its outcomes, particularly in critically ill patients admitted to the ICU. Here’s a detailed explanation of the concept, findings, and clinical implications: ### **Dynamic Lipase Trajectory Patterns** Dynamic lipase trajectory refers to the temporal changes in serum lipase levels over a specific period, rather than relying on a single measurement at one point in time. In the context of acute pancreatitis: - Serum lipase levels are a biomarker for pancreatic enzyme activity, reflecting pancreatic inflammation or injury. - Dynamic trajectories capture how lipase levels rise, fall, or fluctuate during the course of hospitalization, offering a more comprehensive view of disease progression compared to static measurements. In this study, lipase levels were tracked from days 0–7 of hospitalization, and machine learning methods identified three distinct trajectory patterns: 1. **Class 1: Consistently Low Lipase Levels** - These patients had stable, low lipase levels throughout their ICU stay. - They showed the lowest in-hospital mortality rate (12.2%) and represented a less severe biochemical subtype of AP. 2. **Class 2: Extremely High and Variable Lipase Levels** - This group exhibited extremely elevated lipase levels with significant variability over time. - Mortality was higher (17.6%), and these patients were older with greater comorbidities, suggesting a more severe disease course. 3. **Class 3: Moderately Elevated, Fluctuating Lipase Levels** - Patients in this class had moderately high lipase levels with fluctuations during the hospitalization period. - Mortality was the highest (19.2%), indicating a clinically significant association between fluctuating lipase levels and poor outcomes. ### **Machine Learning and Its Role** Machine learning (ML) in this study utilized **Latent Class Trajectory Modeling (LCTM)** to identify patterns in lipase trajectories: - **LCTM** is a statistical technique that clusters patients based on shared temporal trends in their data (e.g., lipase levels over time). - It provides a data-driven approach to uncover hidden subgroups (subphenotypes) within a heterogeneous patient population. - ML tools like LCTM are particularly powerful in analyzing non-linear, complex datasets like ICU patient data, which include dynamic biomarkers, clinical interventions, and outcomes. ### **Lipase Trajectory vs. Single-Point Measurement** Traditionally, lipase levels are used as a diagnostic tool for acute pancreatitis, but their prognostic value has been considered limited. This study challenges that notion by demonstrating: - **Dynamic tracking** of lipase levels over time provides a richer, more informative picture of disease progression and severity compared to static measurements. - Persistently high or fluctuating lipase levels may indicate ongoing pancreatic necrosis, systemic inflammation, and multiorgan involvement, which are associated with worse outcomes. ### **Clinical Implications** 1. **Prognostic Value** - Dynamic lipase trajectories are strongly correlated with in-hospital mortality, with Classes 2 and 3 showing significantly higher risk compared to Class 1. - This trajectory-based approach can help clinicians identify high-risk patients early in their ICU stay, enabling timely interventions. 2. **Real-Time Risk Prediction** - Integrating trajectory monitoring into electronic health records (EHRs) could allow for real-time tracking and risk stratification. - Alerts based on trajectory patterns may guide clinicians in optimizing treatment strategies, such as aggressive management for patients in Classes 2 and 3. 3. **Personalized Patient Management** - Lipase trajectory analysis can contribute to personalized care by tailoring interventions to the biochemical and clinical subtype of AP. - For example, patients in Class 2 may require closer monitoring and management of comorbidities, while those in Class 3 may benefit from targeted therapies addressing systemic inflammation and organ dysfunction. ### **Pathophysiological Insights** The study suggests that persistently high or fluctuating lipase levels may reflect: - **Pancreatic Necrosis**: Severe and ongoing damage to pancreatic tissue. - **Systemic Inflammation**: Elevated inflammatory response contributing to multiorgan failure. - **Multiorgan Involvement**: Progression of AP beyond the pancreas, affecting other vital organs and systems. These findings emphasize the importance of understanding the underlying mechanisms of AP progression and the role of dynamic biomarkers in predicting outcomes. ### **Clinical Utility** Dynamic lipase trajectory monitoring has the potential to be incorporated into clinical practice: - **Enhanced ICU Decision-Making**: By identifying patients with high-risk trajectories, clinicians can prioritize resources and interventions. - **Early Warnings**: Real-time analysis of lipase trends could provide early warnings for deteriorating patients, prompting timely escalation of care. - **Improved Scoring Systems**: Current AP severity scores (e.g., APACHE II, SAPS II) could be augmented with trajectory-based biomarkers for better risk assessment. ### **Limitations** While the study provides compelling evidence, some limitations should be considered: 1. **Retrospective Design**: The study used historical data, which limits causal inference and generalizability. 2. **Single-Center Data**: Findings are based on data from Beth Israel Deaconess Medical Center and may not apply universally. 3. **Measurement Variability**: Lipase measurement frequency varied across patients, potentially introducing bias in trajectory classification. 4. **Immortal Time Bias**: Patients with shorter hospital stays may have been excluded, impacting the results. ### **Conclusion** Dynamic serum lipase trajectory analysis represents a novel and promising approach to understanding and managing acute pancreatitis in ICU patients. By leveraging machine learning techniques, clinicians can uncover hidden subtypes of disease progression, enabling better risk stratification and personalized care. Despite its limitations, this trajectory-based methodology has the potential to improve outcomes in critically ill AP patients and could be integrated into routine clinical practice for enhanced decision-making and monitoring.

Inflammation-based biomarkers and acute severe pancreatitis

Inflammation-based biomarkers such as the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Systemic Immune-Inflammation Index (SII) are gaining attention for their potential to predict the severity of acute pancreatitis (AP), particularly in emergency and clinical settings. Let’s delve into what these biomarkers are, why severity prediction is crucial in acute severe pancreatitis, and how these markers help in identifying the severity of the disease. --- ### **What are NLR, PLR, and SII?** 1. **Neutrophil-to-Lymphocyte Ratio (NLR):** - NLR is calculated by dividing the number of neutrophils by the number of lymphocytes in a blood sample. - It reflects the balance between the pro-inflammatory response (neutrophils) and the anti-inflammatory or regulatory response (lymphocytes). - Elevated NLR indicates heightened inflammatory activity and immune dysregulation, which are hallmarks of severe acute pancreatitis. 2. **Platelet-to-Lymphocyte Ratio (PLR):** - PLR is the ratio of platelet count to lymphocyte count in the blood. - Platelets play a role in inflammation and microvascular dysfunction, while lymphocytes are key components of the immune system. - A high PLR suggests significant inflammation and immune imbalance, often associated with more severe disease. 3. **Systemic Immune-Inflammation Index (SII):** - SII is calculated using the formula: (platelet count × neutrophil count) / lymphocyte count. - It incorporates three major components of the inflammatory response—platelets, neutrophils, and lymphocytes—providing a comprehensive view of systemic inflammation. - Elevated SII levels signal severe inflammation and immune system activation. --- ### **Why is Severity Prediction Important in Acute Severe Pancreatitis?** Acute pancreatitis is an inflammatory condition of the pancreas, ranging from mild, self-limiting cases to severe forms involving systemic inflammation, organ failure, and even death. Early prediction of severity is critical for several reasons: 1. **Prompt Identification of High-Risk Patients:** - Severe acute pancreatitis (SAP) can lead to complications such as multi-organ failure, necrosis, and systemic inflammatory response syndrome (SIRS). Early identification of patients at higher risk allows for timely interventions, such as intensive monitoring, fluid resuscitation, and organ support. 2. **Improved Clinical Outcomes:** - Early and accurate severity prediction enables healthcare providers to allocate resources effectively, prioritize ICU admission, and initiate aggressive treatment strategies to minimize complications, thereby reducing morbidity and mortality. 3. **Guiding Treatment Decisions:** - Severity prediction helps in tailoring the treatment plan. For example, patients with mild acute pancreatitis (MAP) may only require supportive care, while those with SAP need closer monitoring and possibly surgical or endoscopic interventions. 4. **Avoiding Over- or Under-Treatment:** - Overestimating severity can lead to unnecessary interventions, while underestimating it can delay life-saving treatments. Reliable biomarkers like NLR, PLR, and SII offer a simpler, objective way to stratify patients and avoid these pitfalls. 5. **Reducing Healthcare Costs:** - By identifying high-risk patients early, unnecessary diagnostic tests and prolonged hospital stays for low-risk patients can be avoided, optimizing resource utilization. --- ### **How Do NLR, PLR, and SII Help Identify the Severity of Acute Pancreatitis?** These biomarkers serve as accessible, cost-effective tools for early prediction of disease severity. Here’s how they contribute: 1. **Reflecting Inflammatory Response:** - Acute pancreatitis is driven by inflammation. High NLR and PLR levels indicate an exaggerated inflammatory response, with elevated neutrophils (pro-inflammatory) and reduced lymphocytes (anti-inflammatory), which are common in severe forms of the disease. - SII, by combining platelet, neutrophil, and lymphocyte data, provides a broader picture of systemic inflammation. 2. **Correlation with Severity:** - In the study, patients with moderate-to-severe acute pancreatitis (SAP) had significantly higher levels of NLR, PLR, and SII compared to those with mild acute pancreatitis (MAP). This demonstrates a direct correlation between these biomarkers and disease severity. 3. **Diagnostic Thresholds:** - Using receiver operating characteristic (ROC) analysis, the study identified optimal cutoff values for predicting SAP: - **NLR:** 6.23 - **PLR:** 21.14 - **SII:** 2046 - These thresholds can be used to stratify patients into mild or severe categories upon admission. 4. **Sensitivity and Specificity:** - Each biomarker showed a unique diagnostic performance: - **NLR:** Highest sensitivity (77.78%), making it excellent for identifying patients at risk of SAP. - **SII:** Highest specificity (84.29%), meaning it is reliable for ruling out SAP in low-risk patients. - **PLR:** Balanced sensitivity (63.89%) and specificity (78.57%), making it the most effective overall diagnostic tool in this study. 5. **Ease of Use:** - These biomarkers can be quickly derived from routine blood tests, making them practical for emergency settings where time is critical. 6. **Pathophysiological Insight:** - Elevated NLR and PLR reflect immune dysregulation and systemic inflammation. - High SII levels incorporate the effects of platelet-driven microvascular dysfunction, neutrophil-mediated inflammation, and lymphocyte suppression, all of which are key features of severe acute pancreatitis. --- ### **Broader Implications in Clinical Practice** - **Early Triage and Monitoring:** NLR, PLR, and SII can be used to triage patients upon hospital admission, ensuring those at higher risk receive priority care. - **Integration with Guidelines:** International gastroenterological guidelines emphasize the importance of early risk stratification in the first 48 hours of admission. These biomarkers align with such recommendations and provide a simpler alternative to complex scoring systems like BISAP, Ranson’s, and APACHE II. - **Prognostic Value:** These markers not only predict severity but also provide insight into the underlying pathophysiology of the disease, helping clinicians understand the inflammatory and immune processes at play. --- ### **Study Findings and Limitations** The study conducted at Shahid Beheshti Hospital in Iran (2018–2023) concluded that: - **PLR** demonstrated the best diagnostic capability among the three biomarkers. - **NLR** had the highest sensitivity, making it ideal for identifying high-risk patients. - **SII** had the greatest specificity, making it useful for ruling out severe cases. However, the study had limitations, including its single-center, retrospective design and lack of external validation. Despite these limitations, the findings are consistent with prior research and highlight the potential of these biomarkers in clinical practice. --- ### **Conclusion** Inflammation-based biomarkers—NLR, PLR, and SII—offer a simple, cost-effective, and reliable method for predicting the severity of acute pancreatitis. By reflecting the inflammatory and immune responses, these markers enable early risk stratification, guiding timely interventions and improving patient outcomes. Among them, PLR showed the best diagnostic balance, making it particularly valuable for clinical use. These biomarkers can complement existing scoring systems and play a vital role in the early management of acute pancreatitis, especially in resource-limited settings.

Serum HbA1c and infected pancreatic necrosis

To address the relationship between serum HbA1c and infected pancreatic necrosis (IPN), let’s delve into the details of HbA1c, IPN, and their association based on the study findings: --- ### **What is HbA1c?** - **Definition:** HbA1c, or glycated hemoglobin, is a blood test that measures the average blood glucose levels over the past 2–3 months. It reflects the percentage of hemoglobin molecules in red blood cells that are coated with glucose. - **Clinical Significance:** HbA1c is widely used as a marker for long-term glycemic control, especially in diabetic patients. The normal range is typically less than 5.7%, while levels ≥6.5% indicate poor glycemic control and may suggest diabetes. - **Importance in Infection Risk:** Chronic hyperglycemia (high blood sugar levels) indicated by elevated HbA1c is known to impair immune function, making the body more susceptible to infections. --- ### **What is Infected Pancreatic Necrosis (IPN)?** - **Definition:** IPN is a severe complication of acute necrotizing pancreatitis (ANP), characterized by bacterial infection of the necrotic (dead) pancreatic tissue. Necrotizing pancreatitis itself involves the death of pancreatic tissue due to inflammation and ischemia. - **Morbidity and Mortality:** IPN is associated with high rates of complications, systemic inflammation, multiorgan failure, and significant mortality. It is one of the leading causes of death in patients with ANP. - **Clinical Features:** Patients with IPN may experience fever, abdominal pain, systemic inflammatory response syndrome (SIRS), sepsis, and organ dysfunction. Management often requires antibiotics, drainage, or surgical intervention. --- ### **Study Findings: Serum HbA1c and IPN** The study demonstrated a strong association between elevated HbA1c levels (≥6.5%) and the development of IPN in patients with ANP. Below is a detailed explanation of the findings: #### **1. Elevated HbA1c as a Predictor of IPN** - **Incidence of IPN:** Among the 153 ANP patients studied, 31 developed IPN (20.3%). Of these, 80.6% had HbA1c levels ≥6.5%, compared to 38.5% in patients without IPN. - **Independent Predictor:** Multivariate analysis revealed that HbA1c ≥6.5% was an independent predictor of IPN, with a hazard ratio (HR) of 4.10, indicating a more than fourfold increased risk of IPN compared to patients with HbA1c <6.5%. #### **2. Mechanism: How High HbA1c Contributes to Infection** - **Hyperglycemia and Immune Dysfunction:** Chronic hyperglycemia impairs multiple aspects of the immune system: - **Leukocyte Dysfunction:** Reduced recruitment of white blood cells to infection sites. - **Complement System Impairment:** Inadequate activation of the complement cascade, which is critical for bacterial clearance. - **Macrophage Dysfunction:** Impaired phagocytosis and bacterial killing. - **Immunosenescence:** Accelerated aging of immune cells, weakening their ability to respond to infections. - **Endothelial Damage:** Chronic hyperglycemia damages the endothelial glycocalyx (a protective layer lining blood vessels), disrupting intestinal microcirculation and mucosal barriers. This facilitates bacterial translocation, increasing the risk of infection in necrotic pancreatic tissue. #### **3. Hyperglycemia as a Mediator** - **Mediation Analysis:** The study found that hyperglycemia fully mediated the relationship between elevated HbA1c and IPN development. Sustained high glucose levels after hospital admission were the driving factor behind the increased risk of infection. - **First Week Hyperglycemia:** Patients with HbA1c ≥6.5% experienced significantly higher rates of hyperglycemia during the first week of admission (91.7% vs. 23.5% in patients with HbA1c <6.5%). #### **4. Organ Dysfunction and Mortality** - **Systemic Inflammation and Organ Dysfunction:** Elevated HbA1c was associated with worse systemic inflammatory and organ dysfunction severity, as evidenced by higher SOFA and APACHE II scores at admission. - **Complications:** Patients with poor glycemic control had longer hospital stays and higher rates of complications, including gastrointestinal fistulas, intra-abdominal hemorrhage, and multiorgan failure. - **Mortality Risk:** The study reported significantly higher 90-day mortality in patients with HbA1c ≥6.5% (9.7% vs. 1.2% in those with HbA1c <6.5%). This highlights the adverse outcomes linked to poor glycemic control in ANP patients. #### **5. Relationship Between Necrosis and Glycemia** - **Extent of Pancreatic Necrosis:** Patients with necrosis exceeding 50% had more severe hyperglycemia, greater complications, and higher IPN risk. This suggests that extensive pancreatic tissue loss contributes to both metabolic dysfunction (endocrine impairment) and infection susceptibility. - **Causal Pathway:** Hyperglycemia mediated 40.1% of the causal pathway between extensive pancreatic necrosis and IPN development. --- ### **Clinical Implications** - **HbA1c as a Biomarker:** Measuring HbA1c upon admission provides a simple and stable biomarker for early risk stratification of IPN in ANP patients. This can help identify high-risk individuals for proactive interventions. - **Glycemic Control:** Strict glycemic control during hospitalization may reduce the risk of IPN and improve clinical outcomes. Early glucose monitoring and management should be prioritized in patients with elevated HbA1c. - **Infection Prevention:** Patients with poor glycemic control may benefit from targeted infection prevention strategies, including prophylactic antibiotics and enhanced immune support. --- ### **Conclusion** Serum HbA1c is a critical predictor of infected pancreatic necrosis in patients with acute necrotizing pancreatitis. Elevated HbA1c (≥6.5%) reflects chronic hyperglycemia, which impairs immune function, increases infection risk, and worsens systemic inflammation and organ dysfunction. The relationship between HbA1c and IPN is fully mediated by hyperglycemia, emphasizing the need for early HbA1c testing and aggressive glycemic management to reduce morbidity and mortality in this vulnerable patient population.

Genetic Variants Linked to Pancreatic IPMN Development

The study identified genetic variants that are significantly linked to the development of pancreatic intraductal papillary mucinous neoplasms (IPMNs), which are cystic lesions in the pancreas that have the potential to progress into pancreatic adenocarcinoma. ### Key Findings: 1. **Genome-Wide Association Analysis**: - Researchers analyzed genetic data from 68,931 individuals in the Mass General Brigham Biobank, including 2,525 individuals diagnosed with IPMNs. - The analysis focused on common single nucleotide variants (SNVs) with a frequency of at least 5%. 2. **Significant Genetic Locus**: - The study identified a significant genetic association on chromosome 19. - Two specific variants, **rs681343** and **rs601338**, were strongly linked to an increased risk of developing IPMNs. 3. **Validation**: - These findings were validated in an independent cohort of 5,014 individuals, further confirming the association between these variants and IPMN risk. ### Role of FUT2 Gene: The variant **rs601338** occurs in a noncoding exon of the **fucosyltransferase 2 (FUT2)** gene. This variant introduces a **stop codon**, which halts the synthesis of the FUT2 protein. The FUT2 gene is critical for several biological functions: - **Enzyme Function**: FUT2 encodes an enzyme involved in the Lewis antigen system, which plays a role in determining blood group antigens and secretor status. - **Mucin Production**: The enzyme contributes to mucin synthesis, which is important for maintaining ductal homeostasis in the pancreas. - **Regulation of Tumor Markers**: FUT2 influences levels of tumor markers such as carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9), which are often elevated in pancreatic diseases. ### Biological Implications: The study suggests that genetic variations in FUT2 contribute to the development of IPMNs by disrupting mucin synthesis and ductal homeostasis. This disruption may create a favorable environment for the formation of cystic lesions and potentially their malignant transformation. ### Conclusion: The identification of FUT2 variants, particularly rs601338, provides a biologically plausible link between genetic variation, mucin production, and the pathogenesis of pancreatic neoplasms. These findings offer insights into the genetic underpinnings of IPMNs and may aid in the development of targeted screening strategies or therapeutic interventions for individuals at risk of pancreatic cancer.

Pleural effusion, acute pancreatitis and Mortality

Pleural effusion (PE) is a significant clinical finding in patients with acute pancreatitis (AP) and has been shown to be strongly associated with increased severity and mortality in this condition. Here's a detailed explanation of the relationship between pleural effusion, acute pancreatitis, and mortality based on the study findings: ### **Pleural Effusion and Acute Pancreatitis** 1. **Prevalence of Pleural Effusion in AP**: - In the study, pleural effusion was detected in 20.5% of patients with acute pancreatitis within the first 48 hours of diagnosis using thoracic ultrasound (TUS). - The effusions were predominantly anechoic in nature and were classified as moderate in size, with a mean volume of approximately 340 mL on the right side and 310 mL on the left side. - Most pleural effusions were unilateral, with 59% appearing on the left side and 41% being bilateral. 2. **Mechanism of Pleural Effusion in AP**: - Pleural effusion in acute pancreatitis is thought to result from systemic inflammation, increased vascular permeability, and diaphragmatic irritation caused by the inflammatory mediators released during pancreatitis. These processes lead to fluid accumulation in the pleural space. 3. **Ultrasound Findings**: - Thoracic ultrasound proved to be a reliable bedside imaging tool for detecting pleural effusion early in the disease course, even when effusions were small or moderate in size. - Other ultrasound findings, such as atelectasis and B-line patterns, were documented but did not show a significant correlation with mortality like pleural effusion did. --- ### **Pleural Effusion and Disease Severity** 1. **Correlation with Severe AP**: - Patients with pleural effusion had a significantly higher prevalence of severe acute pancreatitis (40.9%) compared to those without pleural effusion (2.4%). - The presence of pleural effusion was strongly associated with organ dysfunction and systemic involvement, as indicated by higher scores on severity assessment tools like APACHE II, Marshall, and BISAP. 2. **Severity Assessment Scores**: - The mean Marshall score was higher in patients with pleural effusion (2.0) compared to those without (1.12), reflecting greater organ dysfunction. - Similarly, the mean APACHE II score was elevated in patients with pleural effusion (8.36 vs. 5.52), further confirming the association between pleural effusion and severe disease. 3. **Atlanta Classification**: - Severe acute pancreatitis, as defined by the Atlanta classification, was more frequent among patients with pleural effusion (31.8%) compared to those without (5.9%). 4. **BISAP Score**: - A BISAP score of ≥3, indicating a higher risk of mortality, was observed in 40.9% of patients with pleural effusion versus only 2.4% of those without. --- ### **Pleural Effusion and Mortality** 1. **Higher Mortality in Patients with Pleural Effusion**: - Mortality was significantly higher in patients with pleural effusion (22.7%) compared to those without pleural effusion (3.5%). - This highlights pleural effusion as a strong predictor of death in acute pancreatitis. 2. **Independent Predictor of Mortality**: - Multivariate regression analysis confirmed that pleural effusion was an independent predictor of mortality, with an odds ratio of 6.89 after adjusting for confounders. - Additionally, each unit increase in the Marshall score raised the odds of mortality threefold, emphasizing the combined prognostic value of pleural effusion and organ dysfunction scores. 3. **Clinical Implications**: - Early detection of pleural effusion using thoracic ultrasound can help identify patients at higher risk of severe disease and mortality, enabling timely interventions to improve outcomes. - Incorporating pleural effusion findings into the management of acute pancreatitis can enhance risk stratification and guide clinical decision-making. --- ### **Advantages of Thoracic Ultrasound for Pleural Effusion Detection** 1. **Non-Invasive and Radiation-Free**: - Thoracic ultrasound is a bedside imaging modality that avoids radiation exposure, making it ideal for critically ill patients. 2. **High Sensitivity**: - TUS is more sensitive than chest X-rays for detecting small pleural effusions, ensuring early identification of high-risk patients. 3. **Ease of Use**: - It can be performed rapidly and repeatedly, providing real-time information about pleural abnormalities. --- ### **Conclusion** Pleural effusion is a critical marker of severity and mortality in acute pancreatitis. Its presence within the first 48 hours of diagnosis strongly correlates with severe disease outcomes, including organ dysfunction and higher mortality rates. Thoracic ultrasound is a valuable tool for detecting pleural effusion early and should be integrated into diagnostic protocols for acute pancreatitis. By identifying patients at higher risk, clinicians can implement timely interventions to improve survival and recovery outcomes. Future studies should focus on validating these findings in multicenter settings and exploring long-term prognostic implications.

TGF-Beta and Chronic Pancreatitis

### **TGF-β and Chronic Pancreatitis** Transforming Growth Factor-Beta (TGF-β) is a multifunctional cytokine that plays a key role in chronic pancreatitis (CP), particularly in driving fibrosis and disease progression. Chronic pancreatitis is marked by inflammation, irreversible fibrosis, and loss of pancreatic function, and TGF-β is central to these processes. #### **Role of TGF-β in Chronic Pancreatitis** 1. **Pancreatic Stellate Cell (PSC) Activation**: - TGF-β activates PSCs, turning them into myofibroblast-like cells that produce excessive extracellular matrix (ECM) proteins like collagen and fibronectin. - Activated PSCs also secrete more TGF-β, creating a **positive feedback loop** that worsens fibrosis. 2. **ECM Deposition and Fibrosis**: - TGF-β promotes ECM accumulation by stimulating collagen production and inhibiting its degradation through tissue inhibitors of metalloproteinases (TIMPs). 3. **Epithelial-Mesenchymal Transition (EMT)**: - TGF-β induces pancreatic epithelial cells to transform into mesenchymal cells, which further contribute to ECM production and tissue remodeling. 4. **Immune Modulation**: - TGF-β suppresses T-cell activity and promotes macrophage polarization into the pro-fibrotic M2 phenotype, perpetuating chronic inflammation. #### **Clinical Implications** - Elevated TGF-β levels correlate with disease severity in CP, making it a potential **biomarker** for fibrosis progression. - Targeting TGF-β signaling is a promising therapeutic strategy to reduce fibrosis. #### **Therapeutic Approaches** - **TGF-β Inhibitors**: Drugs like fresolimumab block TGF-β activity. - **PSC Modulators**: Agents like pirfenidone reduce PSC activation. - **Antioxidants**: Compounds like N-acetylcysteine (NAC) attenuate oxidative stress, which amplifies TGF-β signaling. #### **Challenges** Systemic inhibition of TGF-β may cause side effects like impaired wound healing or immune suppression. Early intervention is crucial, as established fibrosis is difficult to reverse. In summary, TGF-β is a central driver of fibrosis in chronic pancreatitis, making it a critical target for therapeutic strategies aimed at halting disease progression and improving patient outcomes.

Fatty Pancreas and PANDORA Hypothesis

The **PANDORA Hypothesis** (Pancreatic Diseases Originating from Intrapancreatic Fat) is a groundbreaking concept that identifies **fat accumulation within the pancreas**—referred to as **fatty pancreas disease (FPD)**—as a common root cause of numerous pancreatic disorders. It suggests that intrapancreatic fat leads to lipotoxicity, inflammation, and abnormal cellular signaling, resulting in a cascade of pathological effects across various pancreatic structures and functions. ### Key Insights into Fatty Pancreas and PANDORA Hypothesis: #### 1. **Fatty Pancreas as the Core Driver of Pancreatic Diseases** - Fat accumulation in the pancreas disrupts its normal function, leading to various disorders such as **pancreatitis**, **type 2 diabetes**, **pancreatic cancer**, and **exocrine pancreatic insufficiency (EPI)**. - The hypothesis proposes that fatty pancreas serves as the **unifying link** connecting these seemingly distinct conditions, explaining their frequent coexistence and bidirectional relationships. #### 2. **Mechanisms of Damage from Intrapancreatic Fat** - **Lipotoxicity**: Excess fat within the pancreas leads to toxic effects on cells, triggering inflammation in the pancreatic microenvironment. - **Abnormal Cell Signaling**: Fat disrupts normal communication among pancreatic cells, including acinar cells, islets of Langerhans, and stellate cells, resulting in dysfunction and disease progression. #### 3. **Cell-Specific Effects of Fat Accumulation** - **Stellate Cells + Fat → Pancreatic Cancer**: Fat deposition disrupts stellate cell signaling, creating a pro-inflammatory and fibrotic environment that raises the risk of pancreatic cancer. - **Islets of Langerhans + Fat → Type 2 Diabetes**: Lipotoxicity impairs insulin secretion and contributes to insulin resistance, linking fatty pancreas to type 2 diabetes. #### 4. **Progression of Pancreatic Disorders** - **Acute Pancreatitis**: Abnormal communication between acinar cells and lipid droplets triggers acute inflammation. - **Chronic Pancreatitis**: Chronic lipotoxic injury leads to fibrosis and calcification, resulting in chronic pancreatitis. - **Exocrine Pancreatic Insufficiency (EPI)**: Fatty pancreas exacerbates EPI by impairing enzyme production and secretion. - **Diabetes of the Exocrine Pancreas (DEP)**: Fatty pancreas worsens DEP, a subtype of diabetes linked to pancreatic dysfunction. #### 5. **Age and Susceptibility** - Older adults are more prone to fatty pancreas due to age-related changes in fat metabolism, making them more susceptible to pancreatic diseases. #### 6. **Overlapping and Sequential Pancreatic Diseases** - The hypothesis explains why pancreatic diseases often overlap or follow one another. For example, chronic pancreatitis can lead to diabetes, while diabetes and chronic inflammation increase the risk of pancreatic cancer. --- ### The Eight Principles of PANDORA Hypothesis 1. **Fatty pancreas drives most pancreatic diseases.** 2. **Lipotoxicity causes inflammation within the pancreatic microenvironment.** 3. **Abnormal acinar cell communication (lipid droplets) triggers acute pancreatitis.** 4. **Chronic lipotoxic injury leads to fibrosis and calcification (chronic pancreatitis).** 5. **Fat deposition disrupts stellate cell signaling, increasing cancer risk.** 6. **Diabetes of exocrine pancreas (DEP) and exocrine pancreatic insufficiency (EPI) are worsened by fatty pancreas.** 7. **Older adults are more susceptible to pancreatic diseases due to increased fatty pancreas.** 8. **Intrapancreatic fat explains the frequent overlap and sequential occurrence of pancreatic diseases.** --- ### Implications of the PANDORA Hypothesis The PANDORA Hypothesis provides a **unifying framework** for understanding the complex interplay between fatty pancreas and various pancreatic disorders. By identifying intrapancreatic fat as a common denominator, it opens avenues for: - **Early diagnosis** of pancreatic diseases through imaging and biomarkers of fatty pancreas. - **Preventive strategies** targeting fat accumulation in the pancreas, such as lifestyle modifications, dietary interventions, and pharmacological approaches. - **Personalized treatment** of pancreatic disorders based on the underlying role of fatty pancreas. In summary, the PANDORA Hypothesis highlights the critical role of fatty pancreas in driving pancreatic diseases and offers a comprehensive model to understand their origins, progression, and interconnections.

Native Hawaiian pancreatic cancer disparity study

The study on pancreatic cancer disparities among Native Hawaiians, conducted as part of the Multiethnic Cohort Study, revealed significant findings about the heightened risk faced by this population compared to White individuals. Below is a detailed summary of the study and its findings: ### Key Findings: 1. **Elevated Risk of Pancreatic Cancer:** - Native Hawaiians were found to have a **71% higher risk of pancreatic cancer** compared to White individuals, even after adjusting for established risk factors such as diabetes, obesity, smoking, alcohol use, and family history of cancer. - The incidence rates of pancreatic cancer were nearly double in Native Hawaiians (80.2 per 100,000 person-years) compared to Whites (44.6 per 100,000 person-years). 2. **Gender-Specific Risk:** - The elevated risk persisted across both sexes: - **Men:** Hazard Ratio (HR) of 1.54. - **Women:** Hazard Ratio (HR) of 1.85. - This indicates that Native Hawaiian women face an even higher relative risk compared to White women. 3. **Impact of Comorbidities:** - Risk of pancreatic cancer increased with the number of comorbidities (e.g., diabetes, obesity, smoking, alcohol use, or family history of cancer). - Native Hawaiian men with **two or more risk factors** had a **fivefold greater risk** compared to White men without any risk factors (HR 5.17). 4. **Diabetes as a Key Risk Factor:** - Among Native Hawaiian men, diabetes was particularly impactful, tripling the risk of pancreatic cancer. 5. **Genetic and Environmental Contributions:** - Genetic analyses suggested that the elevated risk in Native Hawaiians was **independent of polygenic risk scores**, indicating that other biological or environmental factors may be contributing to the disparity. ### Implications: The study concluded that the disproportionate burden of pancreatic cancer in Native Hawaiians likely stems from the **higher prevalence and cumulative effect of risk factors** in this population, particularly among men. This highlights the need for targeted interventions to address these disparities. ### Recommendations: 1. **Targeted Prevention Strategies:** - Developing culturally tailored prevention strategies to address modifiable risk factors such as diabetes, obesity, smoking, and alcohol use. 2. **Risk-Factor Modification:** - Aggressive efforts to manage and reduce risk factors in high-risk Native Hawaiian populations. 3. **Exploration of Screening:** - Researchers emphasized the potential benefits of exploring pancreatic cancer screening for high-risk Native Hawaiian individuals, given their elevated risk. 4. **Further Research:** - Additional genetic and longitudinal studies are needed to better understand the mechanisms driving these disparities and to identify other potential contributors, whether biological, environmental, or social. ### Conclusion: The findings underscore the urgent need to address the unique health challenges faced by Native Hawaiians, particularly in the context of pancreatic cancer. By focusing on prevention, early detection, and further research, health disparities in this population can be better understood and mitigated.